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A B S T R A C T
Background
Oxidative stress has beenproposed as a key factor involved in the development of pre-eclampsia. Supplementingwomenwith antioxidants
during pregnancy may help to counteract oxidative stress and thereby prevent or delay the onset of pre-eclampsia.
Objectives
To determine the effectiveness and safety of any antioxidant supplementation during pregnancy and the risk of developing pre-eclampsia
and its related complications.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (May 2007), the Cochrane Central Register of Controlled
Trials (The Cochrane Library 2006, Issue 3), MEDLINE (1950 to October 2007) and Current Contents (1998 to August 2004).
Selection criteria
All randomised trials comparing one or more antioxidants with either placebo or no antioxidants during pregnancy for the prevention
of pre-eclampsia, and trials comparing one or more antioxidants with another, or with other interventions.
Data collection and analysis
Two review authors independently assessed trials for inclusion and trial quality and extracted data.
Main results
Ten trials, involving 6533 women, were included in this review, five trials were rated high quality. For the majority of trials, the
antioxidant assessed was combined vitamin C and E therapy. There was no significant difference between antioxidant and control
groups for the relative risk (RR) of pre-eclampsia (RR 0.73, 95% confidence intervals (CI) 0.51 to 1.06; nine trials, 5446 women) or
any other primary outcome: severe pre-eclampsia (RR 1.25, 95% CI 0.89 to 1.76; two trials, 2495 women), preterm birth (before 37
weeks) (RR 1.10, 95% CI 0.99 to 1.22; five trials, 5198 women), small-for-gestational-age infants (RR 0.83, 95% CI 0.62 to 1.11;
five trials, 5271 babies) or any baby death (RR 1.12, 95% CI 0.81 to 1.53; four trials, 5144 babies). Women allocated antioxidants
were more likely to self-report abdominal pain late in pregnancy (RR 1.61, 95% CI 1.11 to 2.34; one trial, 1745 women), require
antihypertensive therapy (RR 1.77, 95% CI 1.22 to 2.57; two trials, 4272 women) and require an antenatal hospital admission for
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hypertension (RR 1.54, 95% CI 1.00 to 2.39; one trial, 1877 women). However, for the latter two outcomes, this was not clearly
reflected in an increase in any other hypertensive complications.
Authors’ conclusions
Evidence from this review does not support routine antioxidant supplementation during pregnancy to reduce the risk of pre-eclampsia
and other serious complications in pregnancy.
P L A I N L A N G U A G E S U M M A R Y
Antioxidants for preventing pre-eclampsia
Pre-eclampsia can occur during pregnancy when women have high blood pressure and protein in their urine. In some cases, it can
lead to poor growth for the baby and premature birth. There can also be serious complications for the woman, sometimes affecting
the liver, kidneys, brain or blood clotting system. Both mother and baby are at risk of mortality. A possible contributing factor to the
development of pre-eclampsia may be the presence of excessive amounts of chemicals called ’free radicals’. Antioxidants, such as vitamin
C, vitamin E, selenium and lycopene, can neutralize free radicals. The review covered 10 trials, involving 6533 women, and looked
at several antioxidants. Overall the review found no reduction in pre-eclampsia, high blood pressure or preterm birth with the use of
antioxidant supplements. When antioxidants were assessed separately, there were insufficient data to be clear about whether there was
any benefit or not, except for vitamin C and E. The current evidence does not support the use of antioxidants to reduce the risk of pre-
eclampsia or other complications in pregnancy, but there are trials still in progress.
B A C K G R O U N D
Hypertensive disorders in pregnancy remain a leading cause of
maternal death worldwide (HMSO 1998; NHMRC 1998). The
majority of deaths occur in the developing world. Pre-eclamp-
sia, defined as hypertension complicated with proteinuria (Gifford
2000), is a multiorgan disease, affecting the liver, kidneys, brain
and blood clotting system. Severe pre-eclampsia often results in
life threatening complications such as eclampsia (fitting) and the
HELLP syndrome, which involves haemolysis, elevated liver en-
zymes and low platelets; however, these complications are rare.
Symptoms of the HELLP syndrome include pain in the upper
right part of the abdomen, fatigue, a general feeling of being un-
well (malaise), nausea, vomiting and increased fluid in the body
tissues. Pre-eclampsia also poses serious health risks for the baby.
Pre-eclampsia is implicated in 12% of cases of intrauterine growth
restriction (Kramer 2000) and is a known antecedent in up to
19% of preterm births. Small-for-gestational-age survivors are at
risk of later health problems, including poor growth in childhood
(McCowan 1999) and in adult life, an increased risk of hyperten-
sion and diabetes (Barker 1993). Preterm birth is the leading cause
of early neonatal death and infant mortality. Preterm survivors are
at risk of serious morbidity such as chronic lung disease and long-
term neurological disability (Donoghue 2000).
Antioxidants are loosely defined as “any substance that, when
present in low concentrations compared to that of an oxidisable
substrate, significantly delays or inhibits oxidation of that sub-
strate” (Diplock 1998). Antioxidants protect proteins and enzymes
from oxidation and destruction by free radicals, and help to main-
tain cellular membrane integrity. Antioxidants can be categorised
as either free radical scavengers that trap or decompose existing free
radicals, or cellular and extracellular enzymes that inhibit peroxi-
dase reactions involved in the production of free radicals (Diplock
1998). Free radical scavengers include vitamin C (ascorbate), vita-
minE (tocopherols), carotenoids and glutathione. Antioxidant en-
zymes include glutathione peroxidase, superoxide dismutase and
catalase, which are dependent on the presence of co-factors such
as selenium, zinc and iron. While antioxidant enzymes are impor-
tant for intracellular defences, non-enzymatic antioxidants are the
major defence mechanism in the extracellular compartment.
The exact cause of pre-eclampsia is unknown. However, a key
factor in the development of pre-eclampsia is inadequate cytotro-
phoblast invasion of the spiral arteries in the uterus leading to
faulty implantation and development of the placenta (Roberts
1993). One consequence of this abnormal placental development
may be reduced placental perfusion, and consequent reduction in
blood flow through the placenta. Various hypotheses have been
put forward to support interventions that might delay or reverse
this process. These include antiplatelet agents and calcium sup-
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plements, topics which are covered by other Cochrane reviews
(Hofmeyr 2006; Knight 2007). More recently, the observation
that women with pre-eclampsia have decreased plasma and pla-
cental concentrations of antioxidants (Hubel 1997; Wang 1996)
has led to the proposal that placental underperfusion may mediate
a state of oxidative stress. This includes overproduction of highly
reactive oxygen molecules or free radicals, depleting the body’s
stores of antioxidants. Oxidative stress, coupled with an exagger-
ated inflammatory response, may result in the release of maternal
factors that result in inappropriate endothelial cell activation and
endothelial cell damage. Endothelial cells line the inside surfaces
of blood vessels and their impairment results in the clinical signs of
pre-eclampsia, such as hypertension and proteinuria. A woman’s
risk of, and response to, oxidative stress depends on various factors.
These include the propensity for small dense low density lipopro-
teins, hyperhomocysteinaemia, a genetically determined poor re-
sistance to oxidative stress, and a dietary deficiency of antioxidants
(Roberts 2001). Supplementing women with antioxidants may
increase their resistance to oxidative stress, and hence could limit
the systemic and uteroplacental endothelial damage seen in pre-
eclampsia. Accordingly, antioxidants have been proposed as po-
tential prophylaxes against pre-eclampsia.
There is limited evidence about the safety of giving antioxidants
to women during pregnancy. In non-pregnant people, there have
been inconsistent findings about the benefits and harms of antiox-
idants. For example, the Heart Protection Study, in which 20,536
high-risk adults took antioxidant vitamins C, E and beta-carotene
or matching placebo for five years, concluded these vitamins ap-
peared to be safe (HPS 2002). Controlled clinical trials of vita-
min E supplementation in adults have also failed to demonstrate
any adverse effects (Bendich 1993). Similarly, the only consistent
side-effect reported from controlled clinical trials of high doses
of vitamin C is diarrhoea (Bendich 1997). Of concern, however,
a recent systematic review of trials evaluating vitamin E supple-
mentation demonstrated harmful effects associated with supple-
mentation (Miller 2005). The review included information for
135,967 men and non-pregnant women supplemented with vi-
tamin E in a range of dosages (16.5 to 2000 international units
(IU) per day). An increase in all cause mortality was seen in in-
dividuals supplemented with 400 or more IU vitamin E per day
for at least one year. This review encompassed trials of vitamin E
supplementation in individuals either at risk of or with established
cardiovascular disease, with Alzheimer’s or early onset Parkinson’s
disease, institutionalised elderly individuals as well as the general
population. The authors cautioned that the results cannot reliably
be generalised to healthy adults including pregnant women, and
for those individuals supplemented with lower dosages or short-
term vitamin E supplementation (less than one year). While these
findings cannot be generalised to healthy pregnant women, they
do highlight the need for controlled evaluation of vitamin E and
other antioxidant supplementation in pregnancy.
Furthermore, while water-soluble antioxidants such as vitamin C
may be easily excreted, lipid soluble antioxidants such as vitamin
E and beta-carotene may accumulate in the body, and in very high
doses may have a toxic effect. Many antioxidant preparations, par-
ticularly antioxidant vitamins, are available in over the counter
preparations, highlighting the possibility for self-medication. The
need to demonstrate safety, as well as effectiveness, during preg-
nancy is particularly important when antioxidants are used in high
doses and are readily available. We need reliable evidence about
short-term and long-term safety for both mother and child before
antioxidants are introduced into routine antenatal care.
Antioxidants, particularly antioxidant vitamins, are relatively in-
expensive to produce and are readily available. For this reason,
antioxidants may be of particular importance for women in low-
income countries, who carry the greatest burden of morbidity and
mortality associated with pre-eclampsia. The aims of this review
are (i) to identify randomised trials evaluating antioxidants for the
prevention of pre-eclampsia and (ii) to investigate the benefits and
hazards of using antioxidants to prevent pre-eclampsia.
O B J E C T I V E S
To determine the effectiveness and safety of any antioxidant sup-
plementation during pregnancy on the risk of:
1. pre-eclampsia;
2. small-for-gestational-age infants;
3. baby death;
4. maternal and neonatal morbidity;
5. long-term development of the child;
6. side-effects and adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised trials comparing one or more antioxidants with
either placebo or no antioxidants during pregnancy for the preven-
tion of pre-eclampsia, and trials comparing one or more antiox-
idants with another, or with other interventions. Trials were in-
cluded if the primary aim of the study was to prevent pre-eclamp-
sia or if the primary aim was otherwise but pre-eclampsia was re-
ported by the authors.
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The previous version of this review included quasi-randomised
studies; however, our protocol stated these would be excluded
when sufficient data from adequately randomised trials became
available. Such data became available for this version of the review,
with the inclusion of two trials involving 4272 women.
Types of participants
Pregnant women considered to be at low, moderate or high risk of
developing pre-eclampsia. Women with established pre-eclampsia
were excluded. Women were classified into subgroups based on:
(1) their level of risk at trial entry of developing pre-eclampsia:
(a) high risk, defined as women having one or more of the follow-
ing: previous severe pre-eclampsia, diabetes, chronic hypertension,
renal disease or autoimmune disease;
(b) moderate/low risk, defined as women who do not meet the
criteria for high risk and have any of the following risk factors, in
particular first pregnancy, a mild rise in blood pressure and no pro-
teinuria, positive roll-over test, abnormal uterine artery Doppler
scan, multiple pregnancy, a family history of pre-eclampsia, ma-
ternal age less than 20 and known thrombophilia.
When the risk was unclear or unspecified women were classified
as moderate/low risk.
(2)Gestation at randomisation: less than 12weeks’ gestation, 12 to
20 weeks’ gestation, 21 to 28 weeks’ gestation and greater than 28
weeks’ gestation. In the previous version of this review, participants
were subgrouped on gestation at randomisation of less than 20
weeks’ gestation or greater than or equal to 20 weeks’ gestation.
This subgroup has been amended to allow an assessment of the
effects of antioxidant supplementation in the first trimester and the
impact on timingof disease progression and severity, particularly as
symptoms of pre-eclampsia usually occur after 20weeks’ gestation.
Types of interventions
1. Comparisons of any antioxidant/s (any dosage regimen)
with either placebo or no antioxidant/s.
2. Comparisons of one or more antioxidant with other
antioxidant/s.
3. Comparisons of antioxidant/s with other interventions.
4. Comparisons of one or more antioxidants with other agents
compared with placebo or no antioxidant/s, other antioxidants
or other interventions.
Trials were classified into subgroups based on:
1. type of antioxidant(s);
2. dose of antioxidant/s (above, within or below accepted
pharmacologic range);
3. antioxidant intake before trial entry, where applicable.
All types of antioxidants, including enzymes that inhibit or retard
the production of oxidative substances or free radical scavengers
that interact with free radicals, were included. In the previous ver-
sion of the review the type of antioxidant was classified as either vi-
tamin, mineral or non-vitamin antioxidants. In this review, all in-
cluded trials except one (Han 1994) assessed vitamin antioxidants,
therefore the subgroup analyses based on antioxidant type classify
trials according to the type of antioxidant vitamin(s) assessed, and
whether the antioxidant(s) was given alone or with other agents.
Types of outcome measures
Primary outcomes
1. Pre-eclampsia: onset before or after 34 weeks, variously
defined by the authors.
2. Severe pre-eclampsia; including HELLP (haemolysis
elevated liver enzymes and low platelets) syndrome and
imminent eclampsia.
3. Preterm birth, very preterm birth and extremely preterm
birth: less than 37 complete weeks’ gestation, less than 33
completed weeks’ gestation or less than 27 completed weeks’
gestation.
4. Small-for-gestational-age infants: whenever possible,
defined as less than the third centile, otherwise the most extreme
centile reported.
5. Baby death (miscarriage, stillbirth, neonatal or infant
death).
Secondary outcomes
For the mother:
death up to six weeks postpartum; gestational hypertension; se-
vere hypertension; use of antihypertensives; elective delivery (in-
duction of labour or elective caesarean section); caesarean section
(emergency plus elective); bleeding episodes (such as abruption
of the placenta, antepartum haemorrhage, postpartum haemor-
rhage, need for transfusion); measures of serious maternal morbid-
ity (including eclampsia, liver failure, renal failure, disseminated
intravascular coagulation, stroke); and maternal views of care.
For the child
Gestational age at birth; birthweight; Apgar score less than seven
at five minutes; Apgar score less than four at five minutes; respi-
ratory distress syndrome; chronic lung disease; bleeding episodes
(such as intraventricular haemorrhage, periventricular leukomala-
cia); bacterial sepsis; necrotising enterocolitis; retinopathy of pre-
maturity; disability during childhood (such as cerebral palsy, in-
tellectual disability, hearing disability and visual impairment); and
poor childhood growth.
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For mother and child
Side-effects and adverse effects of antioxidants sufficient to stop
supplementation; side-effects and adverse effects of supplementa-
tion not sufficient to stop supplementation.
Use of health service resources for the woman
Antenatal hospital admission; visits to day care units; use of inten-
sive care; ventilation and dialysis.
Use of health service resources for the infant
Admission to special care/intensive care nursery; use of mechanical
ventilation; length of stay in hospital; as well as developmental and
special needs after discharge.
Economic outcomes
Costs to health service resources: short term and long term for
both mother and baby; costs to the woman, her family, and society
associated with the interventions.
We added the following outcomes to this updated version of the
review: gestational hypertension, use of antihypertensives, miscar-
riage, extremely preterm birth (before 27 weeks’ completed ges-
tation), Apgar score less than seven at five minutes and economic
outcomes. We included data for these additional outcomes to en-
sure that all outcomes specified in the pre-eclampsia generic pro-
tocol (Meher 2005) are reported in this review.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (May
2007).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. monthly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness search of a further 36 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can be
found in the ’Search strategies for identification of studies’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are given a code (or codes) depending on the topic. The codes are
linked to review topics. The Trials Search Co-ordinator searches
the register for each review using these codes rather than keywords.
In addition, we searched the Cochrane Central Register of Con-
trolled Trials (The Cochrane Library 2006, Issue 3) using the terms
pregnan*, preeclamp*, pre-eclamp*, antioxidant*.
We also searchedMEDLINE (1950 toOctober 2007) andCurrent
Contents (1998 to August 2004) using the strategy:
1. (“antioxidants”[TIAB] NOT Medline[SB]) OR
“antioxidants”[MeSH Terms] OR
“antioxidants”[Pharmacological Action] OR Antioxidant[Text
Word]
2. “ascorbic acid”[MeSH Terms] OR Ascorbic-Acid[Text
Word] OR (“ascorbic acid”[TIAB] NOTMedline[SB]) OR
vitamin C[Text Word]
3. “vitamin e”[MeSH Terms] OR Vitamin-E[Text Word] OR
“alpha-tocopherol”[MeSH Terms] OR alpha-tocopherol[Text
Word]
4. “beta carotene”[MeSH Terms] OR Beta-carotene[Text
Word]
5. “selenium”[MeSH Terms] OR Selenium[Text Word]
6. “glutathione peroxidase”[MeSH Terms] OR Glutathione
peroxidase[Text Word]
7. “superoxide dismutase”[MeSH Terms] OR superoxide
dismutase[Text Word]
8. “catalase”[MeSH Terms] OR catalase[Text Word]
9. “pregnancy”[MeSH Terms] OR pregnancy[Text Word]
10. “pre-eclampsia”[MeSH Terms] OR (“pre-eclampsia”[TIAB]
NOTMedline[SB]) OR preeclampsia[Text Word]
11. “pregnancy complications”[MeSH Terms] OR Pregnancy
complications[Text Word]
12. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
13. #12 AND (#9 OR #10 OR #11)
14. “controlled clinical trial”[Publication Type] OR “controlled
clinical trials”[MeSH Terms] OR “controlled clinical trial”[Text
Word]
15. “randomized controlled trial”[Publication Type] OR
“randomized controlled trials”[MeSH Terms] OR “randomized
controlled trials”[Text Word]
16. #14 OR #15
17. #13 AND #16
We did not apply any language restrictions.
Data collection and analysis
Two review authors assessed potentially eligible trials for their suit-
ability for inclusion in the review. Decisions regarding inclusion
were made separately and results compared. Where review au-
thors were associated with potentially eligible trials (Poston 2006;
Rumbold 2006), decisions regarding suitability for inclusion in
the review were made by a review author not involved in the trial
and by an independent assessor (Philippa Middleton). Any dis-
agreement was resolved through discussion. Data were extracted
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by two authors (neither involved with the individual trial) using
an agreed format, and again discrepancies resolved through dis-
cussion. Data were double-entered and checked.
We assessed the validity of each included trial according to the cri-
teria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2006). Trials were assessed with a grade
allocated to each trial on the basis of allocation concealment: A
(adequate), B (unclear) or C (inadequate). Where the method of
allocation concealment was unclear, attempts were made to con-
tact authors to provide further details.
Blinding, completeness of follow up and use of placebo were as-
sessed for each outcome using the following criteria:
A. double blind, neither investigator nor participant knew or were
likely to guess the allocated treatment;
B. single blind, either the investigator or the participant knew
the allocation. Or, the trial is described as double blind, but side-
effects of one or other treatment mean that it is likely that for a
significant proportion (at least 20%) of participants the allocation
could be correctly identified;
C. no blinding, both investigator and participant knew (or were
likely to guess) the allocated treatment;
D. unclear.
For completeness of follow up:
A. less than 3% of participants excluded;
B. 3% to 9.9% of participants excluded;
C. 10% to 19.9% of participants excluded;
D. excluded: if not possible to present the data by all participants
analysed or if more than 20% of participants excluded.
For use of placebo control:
A. placebo controlled;
B. unclear whether placebo controlled;
C. no placebo control.
Statistical analyseswere carried out using theReviewManager soft-
ware (RevMan 2003), with results presented as summary relative
risks. Where there were missing data for outcomes (either due to
exclusions or losses to follow up),an available case analysis was per-
formed. Tests of heterogeneity between trials were applied to assess
the significance of any differences between trials (I2 greater than
or equal to 50%), and possible causes of any heterogeneity were
explored. Summary relative risks were calculated using a fixed-ef-
fect model. If heterogeneity was detected, subgroup analyses for
the primary outcomes were performed by risk of pre-eclampsia,
gestational age at trial entry, type of antioxidant used, antioxidant
dosage and prior dietary intake of antioxidants.Heterogeneity that
was not explained by subgroup analyses was modelled using ran-
dom-effects analysis.
Subgroup analyses based on antioxidant dosage involved classify-
ing trials according to whether dose was above, within or below
accepted pharmacological range. For vitamin C, maximum circu-
lating concentrations of vitamin C in the body have been show
to result from taking vitamin C in doses ranging from 400 mg
(Levine 2001) to 1000 mg (Levine 1996). For vitamin E, an oral
dose of 400 international units has been shown to have antioxi-
dant effects (Devaraj 1997). However, for the other antioxidants
assessed in this review, little is currently known about effective
pharmacological doses.
All included trials were included in the initial analyses and sensi-
tivity analyses carried out to explore the effect of trial quality. This
involved analysis based on an ’A’ rating of allocation concealment,
blinding of assessment of outcome and placebo control. The re-
sults of high-quality studies were compared with overall results for
all included trials.
Our prespecified subgroup analyses for the primary outcomeswere
based on comparing:
(a) women who are at low/moderate or high risk of pre-eclampsia;
(b) women’s gestation at randomisation (less than 12 weeks’ gesta-
tion, 12 to 20 weeks’ gestation, 21 to 28 weeks’ gestation, greater
than 28 weeks’ gestation or other);
(c) the type of antioxidant supplement(s) (vitamin C and E alone,
vitamin C and E with other agents, vitamin C alone, lycopene,
red palm oil, selenium);
(d) the dosage of the antioxidant supplement(s) (above, within or
below accepted pharmacological range);
(e) women who have low or adequate dietary antioxidant(s) intake
(where applicable) before trial entry.
If antioxidants are effective, the subgroup analyses will determine
which of these agents are best, what is the ideal dose, and to com-
pare antioxidants with other interventions.
The planned subgroup analyses aimed to explore the impact of
differences in characteristics of women involved and in the an-
tioxidant treatment assessed. However, for many of the subgroups
there was either insufficient information in the trial publications to
allow data extraction for discrete subgroups (for example, specific
gestational age categories) or it was unclear whether information
that would enable classification into subgroups was collected (such
as women’s dietary intake of antioxidants). For future updates of
this reviewwe plan towrite to the trialists who conducted the stud-
ies in this review. In doing so, we will request further information
to allow data extraction for the subgroups specified in this review
and request any additional data that have been collected but not
already published about outcomes of interest to this review (such
as maternal side-effects), to ensure there is complete capture of the
data about antioxidants.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
See tables ’Characteristics of included studies’ and ’Characteristics
of excluded studies’ for details of individual studies.
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Ten trials, involving 6533 women, were included in the review (
Beazley 2002; Chappell 1999; Han 1994;Mahdy 2004;Merchant
2005; Poston 2006; Rivas 2000; Rumbold 2006; Sharma 2003;
Steyn 2002).
Participants
Half the women (3307, 52%) in this review were at moderate/
low risk of developing pre-eclampsia at trial entry. Five reports
stated that women at “high or increased risk of pre-eclampsia”
were enrolled (Beazley 2002; Chappell 1999; Han 1994; Poston
2006; Rivas 2000). Of these, four studies listed their criteria for
determining risk status, and the criteria varied considerably. They
included: previous pre-eclampsia, chronic hypertension, insulin
requiring diabetes mellitus or multiple gestation (Beazley 2002);
abnormal uterine artery doppler at 18 to 22 weeks’ gestation or
a history in the preceding pregnancy of pre-eclampsia necessitat-
ing delivery before 37 weeks’ gestation, eclampsia or the HELLP
(haemolysis elevated liver enzymes and low platelets) syndrome
(Chappell 1999); pre-eclampsia in the pregnancy preceding the
index pregnancy, requiring delivery before 37 completed weeks’
gestation; diagnosis of HELLP syndrome in any previous preg-
nancy at any stage of gestation; eclampsia in any previous preg-
nancy at any stage of gestation; essential hypertension requiring
medication, currently or previously; maternal diastolic blood pres-
sure of 90 mmHg or more before 20 weeks’ gestation in the cur-
rent pregnancy; type 1 or 2 diabetes, requiring insulin or oral hy-
poglycaemic therapy before the pregnancy; antiphospholipid syn-
drome; chronic renal disease; multiple pregnancy; abnormal uter-
ine artery doppler waveform (18 to 22 weeks’ gestation) or prim-
iparity with a body-mass index of 30 kg/m2 or more at first ante-
natal visit (Poston 2006); and nulliparity, previous pre-eclampsia,
obesity, hypertension, less than 20 years old, diabetes, nephropa-
thy, mean arterial pressure above of 85 mmHg, positive roll-over
test, black race, family history of hypertension or pre-eclampsia,
twin pregnancy and poor socioeconomic conditions (Rivas 2000).
These studies are grouped as moderate/high risk in this review,
as they included high- and moderate-risk women. Nevertheless,
most women actually recruited to these studies were probably high
risk, as 16% in the control group developed pre-eclampsia, com-
paredwith 6% for the studies enrollingmoderate/low-riskwomen.
However, the reported incidence of pre-eclampsia may be influ-
enced by differences in the definitions of pre-eclampsia used in
each study.
Two trials (351 women) recruited women exclusively between
12 and 20 weeks’ gestation, including between 14 to 20 weeks’
(Beazley 2002) and between 16 to 20 weeks’ (Sharma 2003).
The remaining studies all recruited women both before and af-
ter 20 weeks’ gestation, including between 12 to 27 weeks’ ges-
tation (Merchant 2005), 14 to 21+6 weeks’ gestation (Poston
2006; Rumbold 2006) and 16 to 22 weeks’ gestation (Chappell
1999), while other studies merely stated below 16 weeks’ gesta-
tion (Mahdy 2004), below 26 weeks’ gestation (Steyn 2002) or
below 29 weeks’ gestation (Rivas 2000). One trial merely reported
women were recruited “during late pregnancy” (Han 1994). No
trials recruited women prior to 12 weeks’ gestation. There are in-
sufficient data to assess the effects of antioxidants in the prespeci-
fied subgroups based on gestation at trial entry (less than 12 weeks,
12 to 20 weeks, 21 to 28 weeks, greater than 28 weeks); none of
the included trials reported results by gestation at trial entry that
would enable classification into these subgroups. In this review,
the gestational age subgroups reported are the gestational age cat-
egories reported by individual trials.
Interventions
One or more vitamins were the antioxidants evaluated in nine
trials (6212 women). One small study (100 women) evaluated the
mineral selenium. The interventions assessed were vitamin C and
E (Beazley 2002; Chappell 1999; Poston 2006; Rumbold 2006),
vitamin C alone (Steyn 2002), vitamin C and E plus fish oil and
aspirin (Rivas 2000), multivitamin containing vitamin C and E
(Merchant 2005), lycopene (Sharma 2003), red palm oil (Mahdy
2004) and selenium (Han 1994). For vitamin C, the daily dosages
varied from 500 mg to 1000 mg. For vitamin E, all trials except
one (Merchant 2005) used a daily dosage of 400 international
units. For selenium the daily dose was 100 µg and for lycopene 4
mg. For the one trial assessing red palm oil, no information about
dosage was provided.
Outcomes
Definition of pre-eclampsia
Eight of the trials (5346 women) reported pre-eclampsia as an out-
come (Beazley 2002; Chappell 1999; Mahdy 2004; Poston 2006;
Rivas 2000; Rumbold 2006; Sharma 2003; Steyn 2002), although
four of these did not say how they defined pre-eclampsia (Beazley
2002; Mahdy 2004; Rivas 2000; Steyn 2002). Two studies did
not report pre-eclampsia. One study (109 women) reported preg-
nancy-induced hypertension and proteinuria (Han 1994), we have
used the data for proteinuria in this review, on the assumption
that it probably represents pre-eclampsia. The other trial (1078
women) reported hypertension occurring at any time in pregnancy
but no proteinuria or other symptoms of pre-eclampsia (Merchant
2005). We have included data for this trial in the gestational hy-
pertension outcome.
Three trials (Chappell 1999; Poston 2006; Sharma 2003) defined
pre-eclampsia according to the definitions specified by the Inter-
national Society for the Study of Hypertension in Pregnancy (two
recordings of diastolic blood pressure of 90 mmHg or above at
least four hours apart plus proteinuria defined as excretion of 300
mg or more in 24 hours or two readings of 2+ or higher on dip-
stick analysis). One trial (Rumbold 2006) defined pre-eclampsia
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according to the definition specified by the Australian Society for
the Study of Hypertension in Pregnancy (two occasions of systolic
blood pressure of at least 140 mmHg or diastolic blood pressure
of at least 90 mmHg, or both, and one or more of: proteinuria,
renal insufficiency, liver disease, neurological problems, haemato-
logical disturbances or fetal growth restriction). No trials reported
the timing of onset of pre-eclampsia (either prior to or after 34
weeks’ gestation), two trials (Beazley 2002; Poston 2006) reported
severe pre-eclampsia.
Other outcomes
Five trials reported preterm birth (Beazley 2002; Chappell 1999;
Poston 2006; Rumbold 2006; Steyn 2002) and small-for-gesta-
tional-age infants as birthweight less than the 10th centile (Beazley
2002; Chappell 1999; Poston 2006; Rumbold 2006; Sharma
2003). Four trials reported any baby death (Chappell 1999; Poston
2006; Rumbold 2006; Steyn 2002), including miscarriage, still-
birth or neonatal death. One trial (Beazley 2002) reported “there
were no pregnancy losses before 20 weeks’ gestation”, but provided
no information about either stillbirth or neonatal death. No trials
reported infant death (death after 28 days of life).
Secondary outcomes
Data for the secondary outcomes were poorly reported. For many
outcomes, data were reported by one or two trials only. No trials
reported maternal views of care or views about the acceptability
of the intervention. Similarly, no trials reported bacterial sepsis in
the infant, disability during childhood or poor childhood growth.
Excluded trials
Twenty-two studieswere excluded from the review. Six studieswere
excluded as women involved had established pre-eclampsia at trial
entry (Anthony 1996; Gulmezoglu 1997; Morrison 1984; Roes
2006; Sawhney 2000; Sikkema 2002); four studies were excluded
as the interventions assessed were not considered to have direct an-
tioxidant properties (Ferguson 1955; Herrera 1993; Marya 1987;
Theobald 1937); three studies were non-randomised or quasi-ran-
domised (Bolisetty 2002; People’s League 1942; Powers 2000);
seven studies did not report any clinically meaningful outcomes or
pre-eclampsia (Borna 2005; Casanueva 2005; Dijkhuizen 2004;
Pawlowicz 2000; Pressman 2003; Radhika 2003; Thomson 2001)
and two studies (Chaudhuri 1969; West 1999) had greater than
20% losses to follow up.
Risk of bias in included studies
Five trials (Chappell 1999; Poston 2006; Rumbold 2006; Sharma
2003; Steyn 2002) fulfilled all of the criteria for a high-quality
trial, that is theywere rated ’A’ for allocation concealment; women,
caregivers and research staff were blinded to treatment allocation;
had less than 3% of participants excluded and were placebo con-
trolled. Five trials were not rated high quality (Beazley 2002; Han
1994;Mahdy 2004;Merchant 2005; Rivas 2000); these trials were
excluded from the sensitivity analyses.
Randomisation and allocation concealment
Formal randomisation was reported in five trials by use of third-
party randomisation (Chappell 1999; Poston 2006; Rumbold
2006; Sharma 2003; Steyn 2002), that is women were allocated
to each group either by an individual not directly involved in the
research or via telephone or computer allocation. The degree of
allocation concealment for these five trials was therefore adequate.
For the other five trials (Beazley 2002; Han 1994; Mahdy 2004;
Merchant 2005; Rivas 2000), the degree of allocation concealment
was unclear, as no information was provided about the methods
of randomisation and allocation concealment.
Blinding
Six trials explicitly stated that women, caregivers and researchers
were blinded to treatment allocations (Chappell 1999; Merchant
2005; Poston 2006; Rumbold 2006; Sharma 2003; Steyn 2002).
Two trials stated “double-blind” in the text (Beazley 2002; Mahdy
2004) while the other trial used the term “triple-blind” in the text
(Rivas 2000). The degree of blinding, if any, was unclear for one
trial (Han 1994).
Completeness of follow up
Three trials reported outcomes for all randomised women ac-
cording to treatment allocation (Chappell 1999; Rumbold 2006;
Sharma 2003) and another four did not mention any losses to
follow up (Han 1994; Mahdy 2004; Rivas 2000; Steyn 2002). In
the three remaining trials, losses to follow up were less than 1%
(Poston 2006), 8% (Beazley 2002) and 19% (Merchant 2005).
Use of placebo
All trials used a placebo control.
Effects of interventions
Ten trials, involving 6533 women, compared any antioxidant sup-
plementation with placebo (Beazley 2002; Chappell 1999; Han
1994; Mahdy 2004; Merchant 2005; Poston 2006; Rivas 2000;
Rumbold 2006; Sharma 2003; Steyn 2002). In view of the hetero-
geneity in results for pre-eclampsia, small-for-gestational-age in-
fant, gestational hypertension, bleeding episodes, gestational age
at birth, birthweight, necrotising enterocolitis and respiratory dis-
tress syndrome, a random-effects model was used for these out-
comes.
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Primary outcomes
Pre-eclampsia
There was no clear difference in the relative risk (RR) of pre-
eclampsia between antioxidant supplemented and control groups
using a random effects model (RR 0.73, 95% confidence inter-
vals (CI) 0.51 to 1.06; nine trials, 5446 women) or a fixed ef-
fects model (RR 0.88, 95% CI 0.75 to 1.02). This result was not
significantly different in the sensitivity analysis restricted to high-
quality studies (RR 0.82, 95% CI 0.58 to 1.16; five trials, 5006
women). Similarly, there were no clear differences between groups
for moderate/low-risk women (RR 0.85, 95% CI 0.48 to 1.51;
four trials, 2441 women) ormoderate/high-risk women (RR 0.56,
95% CI 0.29 to 1.11; five trials, 3005 women). There are insuffi-
cient data to assess the effects of antioxidants in subgroups based
on gestation at trial entry (less than 12 weeks, 12 to 20 weeks, 21
to 28 weeks, greater than 28 weeks); most trials included women
in some or all of these gestational age subgroups, but did not re-
port results by gestation at trial entry. The two largest trials (4272
women) recruited women between 14 and 21+6 weeks’ gestation,
and showed there was no clear difference in the RR of pre-eclamp-
sia between treatment groups (RR 1.01, 95% CI 0.86 to 1.20).
The other subgroups by gestational age at trial entry should be
interpreted with caution, as the numbers are small.
There was no clear difference between the groups for women al-
located vitamin C and E alone (RR 0.92, 95% CI 0.68 to 1.25;
four trials, 4655 women). All of the other subgroups by type of
antioxidant should be interpreted with caution, as the numbers
are small. Nevertheless, the RR of pre-eclampsia was reduced for
women allocated lycopene (RR 0.48, 95% CI 0.24 to 0.97; one
trial, 251 women) and for women allocated vitamin C and E com-
bined with aspirin and fish oil (RR 0.07, 95% CI 0.01 to 0.54;
one trial, 127 women) rather than placebo. There were no clear
differences between the treatment groups for women allocated vi-
tamin C alone (RR 1.00, 95% CI 0.21 to 4.84; one trial, 200
women), red palm oil (RR 0.73, 95% CI 0.07 to 7.80; one trial,
113 women) or selenium (RR 0.10, 95% CI 0.01 to 1.86; one
trial, 100 women).
There were insufficient data to assess the possible impact of an-
tioxidant dose or dietary intake of antioxidants at trial entry. All
of the included trials used a daily dose of vitamin C considered
to be within pharmacological range. For vitamin E, only one trial
used a daily dosage considered to be below pharmacological range
(Merchant 2005), however, the only outcome reported by this
trial was gestational hypertension. Only one trial (Rumbold 2006)
(1877 women) reported information about women’s dietary in-
take at trial entry, where approximately 94% of women in both
groups had an adequate intake of vitamin C, and 43% of women
in both groups had an adequate intake of vitamin E at trial entry.
Therefore, subgroup analyses based on antioxidant dose and di-
etary intake were not undertaken.
Severe pre-eclampsia
There was no clear difference in the RR of severe pre-eclampsia
(RR 1.25, 95%CI 0.89 to 1.76; two trials, 2495 women) between
antioxidant and control groups. Sensitivity analysis based on qual-
ity included one trial (2395 women), the RR of severe pre-eclamp-
sia for women allocated antioxidants was 1.26 (95% CI 0.89 to
1.79). Only two trials reported on severe pre-eclampsia, therefore
the effect of antioxidants in subgroups is unclear; no data were
available for women at moderate/low risk or for women allocated
antioxidants other than vitamin C and E alone.
Preterm birth
Antioxidants were associated with a small increase in the RR of
any preterm birth (RR 1.10, 95%CI 0.99 to 1.22; five trials, 5198
women), although this finding did not reach statistical significance
(P = 0.07). There was no significant difference between treatment
groups for the RR of very preterm birth (less than 34 weeks’ gesta-
tion) (RR 1.19, 95% CI 0.98 to 1.45; two trials, 4651 women) or
extremely preterm birth (less than 28 weeks’ gestation) (RR 1.07,
95% CI 0.55 to 2.06; two trials, 2077 women) between antiox-
idant supplemented and control groups. Similarly, there was no
significant difference in the RR of any preterm birth in the sensi-
tivity analysis restricted to high-quality studies (RR 1.10, 95% CI
0.98 to 1.22; four trials, 5098 women) or in the subgroup analyses
for moderate/low-risk women (RR 1.17, 95% CI 0.92 to 1.48;
two trials, 2067 women) or moderate/high-risk women (RR 1.09,
95% CI 0.97 to 1.22; three trials, 3131 women).
There was no significant difference in the RR of preterm birth
between antioxidant and control groups for any of the subgroups
based on gestation at trial entry. The only exception was an ap-
parent increase in the RR for women enrolled at “less than 26
weeks’ gestation” (RR 1.43, 95% CI 1.03 to 1.99; one trial, 200
women). Data for this subgroup should be interpreted with cau-
tion as they are based on one small trial (200 women). There was
no clear difference between treatment groups for women allocated
vitamin C and E alone (RR 1.08, 95% CI 0.96 to 1.20; four trials,
4998 women). However, the RR of preterm birth was increased
for women allocated vitamin C alone (RR 1.43, 95% CI 1.03 to
1.99; one trial, 200 women); this is same trial that enrolledwomen
at less than 26 weeks’ gestation. The data should be interpreted
with caution as the numbers are small. No data were available for
women allocated antioxidants other than vitamin C and E or vi-
tamin C alone.
Small-for-gestational-age infants
There was no clear difference between antioxidant and control
groups for the RR of having a small-for-gestational-age infant (RR
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0.83, 95%CI0.62 to 1.11; five trials, 5271 babies). Similarly, there
was no clear difference in risk in the sensitivity analyses restricted
to high-quality studies (RR 0.84, 95% CI 0.63 to 1.13; four trials,
5171 babies) or in the subgroup analyses for moderate/low-risk
women (RR 0.71, 95% CI 0.42 to 1.19; two trials, 2104 babies)
or moderate/high-risk women (RR 0.92, 95% CI 0.63 to 1.34;
three trials, 3167 babies).
For women recruited between 12 and 20 weeks’ gestation the
RR of the baby being small-for-gestational age was reduced for
women allocated antioxidants (RR0.50, 95%CI 0.29 to 0.87; two
trials, 351 babies). However, these data should be interpreted with
caution as the numbers are small. There was no clear difference
between the treatment groups in the RR of small-for-gestational-
age infants for any other gestational age subgroups. There was no
clear difference between treatment groups for women allocated
vitamin C and E alone (RR 0.93, 95% CI 0.73 to 1.19; four trials,
5020 babies); however, the risk of small-for-gestational-age infants
was reduced for women allocated lycopene (RR 0.51, 95% CI
0.29 to 0.91; one trial, 251 babies). Again, these data should be
interpreted with caution as the numbers are small. No data were
available for women allocated antioxidants other than vitamin C
and E or lycopene.
Baby death
There was no clear difference between antioxidant and control
groups in theRRof any baby death (RR1.12, 95%CI0.81 to 1.53;
four trials, 5144 babies), or when any baby death was subgrouped
on timing of death, including miscarriage or stillbirth (RR 1.32,
95% CI 0.92 to 1.90; four trials, 5144 babies) or neonatal death
(RR 0.59, 95% CI 0.28 to 1.23; three trials, 4748 babies).
All of the trials reporting on baby death were rated high quality.
There was no clear difference in the RR of baby death for mod-
erate/low-risk women (RR 0.90, 95% CI 0.53 to 1.51; two trials,
2077 babies) or moderate/high-risk women (RR 1.27, 95% CI
0.85 to 1.90; two trials, 3067 babies). Similarly, there was no clear
difference in the RR of baby death for any of the gestational age
subgroups or the subgroups based on antioxidant type; however,
no datawere available for women allocated antioxidants other than
vitamin C and E or vitamin C alone.
Other outcomes
One trial (Rumbold 2006) reported there were nomaternal deaths
in either the antioxidant or control group (1877 women) and an-
other trial (Poston 2006) reported two maternal deaths (one in
each group), however both deaths were unrelated to pre-eclamp-
sia. There were no clear differences between groups for the RR of
gestational hypertension (RR 0.89, 95% CI 0.62 to 1.26; seven
trials, 5817 women) or severe hypertension (RR 1.39, 95% CI
0.85 to 2.30; two trials, 4272 women); however, women allocated
antioxidants were more likely to require antihypertensive therapy
(RR 1.77, 95% CI 1.22 to 2.57; two trials, 4272 women). There
were no clear differences between groups for any other outcomes
including elective delivery (RR 1.11, 95% CI 0.99 to 1.25; two
trials, 2077 women); caesarean section (RR 1.02, 95% CI 0.87 to
1.18; one trial, 1877 women); bleeding episodes (RR 1.28, 95%
CI 0.35 to 4.68; three trials, 2360 women); serious maternal mor-
bidity (RR 1.22, 95% CI 0.39 to 3.81; three trials, 4523 women);
gestational age at birth (weighted mean difference (WMD) 0.26
weeks, 95% CI -0.84 to 1.36; three trials, 3135 women); birth-
weight (WMD 14.60 grams, 95% CI -61.99 to 91.18; five trials,
5089 women); Apgar score at five minutes: low (less than seven)
(RR 1.63, 95% CI 0.92 to 2.87; one trial, 2784 infants), very low
(less than four) (RR 0.92, 95% CI 0.41 to 2.07; two trials, 4651
infants); respiratory distress syndrome (RR 0.48, 95% CI 0.08 to
2.85; two trials, 4567 women); chronic lung disease (RR 0.20,
95% CI 0.02 to 1.72; one trial, 1853 infants); neonatal bleeding
episodes (RR 0.61, 95%CI 0.29 to 1.29; two trials, 4637 infants);
necrotising enterocolitis (RR 1.10, 95% CI 0.09 to 13.15; two
trials, 4567 women) or retinopathy of prematurity (RR 0.88, 95%
CI 0.31 to 2.50; two trials, 4567 infants).
Only one trial (Rumbold 2006) reported maternal side-effects.
Women allocated antioxidants in this trial were more likely to self-
report abdominal pain late in pregnancy (RR 1.61, 95% CI 1.11
to 2.34; one trial, 1745 women); however, the trial reported there
were no differences in any other self-reported side-effects between
antioxidant and control groups. Use of health service resources for
women or infants was variously reported by three trials (Poston
2006; Rumbold 2006; Steyn 2002). There was no overall effect on
the use of health service resources for either the woman or infant
except for antenatal hospital admission for hypertension. Women
allocated antioxidants were more likely to require an antenatal
hospital admission for hypertension (RR 1.54, 95% CI 1.00 to
2.39; one trial, 1877 women).
Heterogeneity
To explore potential sources of heterogeneity we undertook pre-
specified sensitivity and subgroup analyses investigating the im-
pact of: methodological variation; clinical variation, including dif-
ferences in women’s baseline risk of pre-eclampsia and dietary in-
take of antioxidants at trial entry; and variation in treatment char-
acteristics, including duration of antioxidant therapy (related to
gestational age at trial entry), and the type and dosage of antioxi-
dant assessed.
Differences in the quality of trials included in this review are un-
likely to be amajor source of heterogeneity; there was no difference
in the effect of antioxidants in the sensitivity analysis restricted
to high-quality trials. Furthermore, none of the prespecified sub-
groups explored in this review clearly explain the heterogeneity.
There was no significant difference in the effects of antioxidants for
women atmoderate/low risk or moderate/high risk of pre-eclamp-
sia. For the other subgroup analyses, there were insufficient data
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to adequately explore the effects of antioxidants in all subgroups.
Nevertheless, differences in the type of antioxidant assessed may
have contributed to the heterogeneity, as the magnitude of the ef-
fect of antioxidants was greater for women allocated lycopene and
for women allocated vitamin C and E combined with aspirin and
fish oil, compared with women allocated vitamin C and E alone.
The possible factors contributing to heterogeneity may become
clearer when the results of currently ongoing trials are available.
D I S C U S S I O N
Uncertainty remains about the effects of antioxidants for the pre-
vention of pre-eclampsia and its related complications. Routine
use of antioxidant supplements in pregnancy should only be con-
sidered if antioxidants are shown to be associated with substantive
benefits for the mother or baby, or both; none have been con-
sistently demonstrated in this review. The point estimate for the
effect of antioxidant supplements on pre-eclampsia was a 27% re-
duction in the relative risk, however, the 95% confidence interval
for the true effect ranged from a 49% reduction to a 6% increase,
when compared with the control group. There was no clear dif-
ference between antioxidant and control groups for the risk of
other perinatal complications, including small-for-gestational-age
infants and baby death.
Formany outcomes, including pre-eclampsia, the effects of antiox-
idants were not consistent across trials, and there was significant
statistical heterogeneity. Differences in the type of antioxidant as-
sessed may be one source of this heterogeneity, as the magnitude
of effect of antioxidants on the relative risk of pre-eclampsia was
much greater for women allocated lycopene (52% reduction) and
for women allocated vitamin C and E combined with aspirin and
fish oil (93% reduction) compared with women allocated vitamin
C and E alone (8% reduction). However, the subgroup data on
heterogeneity related to antioxidant type should be interpreted
with caution. The number of women included in the subgroups
for types of antioxidants other than combined vitamin C and E
was small, resulting in the potential to be misled by bias and ran-
dom error. Much more information is needed to assess the effects
of antioxidants other than vitamin C and E on the risk of pre-
eclampsia and other complications.
The majority of data in this review are contributed to by two
large trials assessing combined vitamin C and E therapy (Poston
2006; Rumbold 2006), therefore it is likely that differences be-
tween these studies are contributing to the heterogeneity. There
are clear differences between these studies in participant character-
istics; one trial enrolled nulliparous women with a singleton preg-
nancy (Rumbold 2006), the other enrolled women at increased
risk of pre-eclampsia based on a range of risk factors (Poston 2006).
Subgroup analyses compared the effects of antioxidants for mod-
erate/low-risk women and moderate/high-risk women, and found
no overall difference between these subgroups. However, in the
moderate/high-risk group, the incidence of pre-eclampsia in con-
trol groups ranged from8%to22%, suggesting a range ofmaternal
risk. It is possible that the effects of antioxidants are different for
women with specific risk factors, and this may also contribute to
the heterogeneity. However, there is insufficient detail in the trial
publications to extract data for specific risk factors, and therefore
further assess the effects of antioxidants for women at different
baseline risk. Undertaking a review based on data from individual
women may help to determine if the effects of antioxidants are
different for women at different baseline risk.
The heterogeneity found may also be related to study size; the
majority of the small studies included in this review had posi-
tive results. Therefore, there may be publication bias, where small
studies that failed to show an effect for antioxidants have not be-
ing published. When the effect size reported by trials is plotted
against the trial sample size, the resulting graph (funnel plot) for
the risk of pre-eclampsia is asymmetric (Figure 1), suggesting that
data from small negative trials are missing. It is also possible that
differences between trials in women’s risk status at trial entry and
the type of antioxidant assessed are contributing to funnel plot
asymmetry. However, caution must be taken when interpreting
the funnel plot asymmetry. Our assessment of publication bias was
not prespecified and post-hoc investigations are more susceptible
to bias.
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Figure 1. Funnel plot of the effects of antioxidants for preventing pre-eclampsia
Antioxidants were associated with an increased risk of antihy-
pertensive therapy and antenatal admission for hypertension. Al-
though these findings raise concern about the safety of antioxi-
dants in pregnancy, they were not clearly reflected in an increase
in the risk of other hypertensive complications in pregnancy in-
cluding pre-eclampsia, gestational hypertension or in the use of
health services such as intensive care. It is therefore possible that
these results reflect reporting bias, as only two studies reported on
use of antihypertensives and only one study reported specifically
on hospital admission for hypertension.
Antioxidants also appeared to be associated with a small increase in
the risk of preterm birth, although this result is strongly influenced
by one small trial evaluating vitamin C alone for women already
at high risk of giving birth preterm (Steyn 2002). The effect is
not statistically significant for studies evaluating vitamin C and
E alone. There was no significant difference in the relative risk
of preterm birth for other types of antioxidants, and importantly,
there was no increase in adverse neonatal outcomes associated with
any type of antioxidants. Nevertheless, further evidence is needed
to clearly demonstrate that antioxidants do more good than harm.
Women allocated antioxidants were also more likely to self-report
abdominal pain in late pregnancy, although this outcome was only
reported by one trial (Rumbold 2006). We are unaware of any
other studies reporting an association between antioxidants and
abdominal pain. Although this potential side-effect did not stop
women taking antioxidant supplements, these findings highlight
the need to assess potential side-effects and adverse effects in trials.
None of the included trials reported on the acceptability of the
intervention to women.
Data were poorly reported for many of the secondary outcomes,
particularly substantive measures of morbidity for the baby. From
the available data, there were no significant differences between
groups for serious infant outcomes, including respiratory distress
syndrome, necrotising enterocolitis, neonatal bleeding episodes
and retinopathy of prematurity, although the direction of effect
for most neonatal outcomes favoured antioxidants.
Results of the current ongoing trials will help to clarify whether
antioxidant supplementation overall results in benefit or harm,
and whether the effects of antioxidants are mediated by specific
maternal risk factors and the type, dosage and timing of antioxi-
dant supplementation.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Evidence from this review does not support routine antioxidant
supplementation during pregnancy to reduce the risk of pre-
eclampsia and other serious complications in pregnancy.
Implications for research
Further large trials should not be initiated until the results of
currently ongoing trials (see below) become available. Data from
these studies should clarify whether or not antioxidants have any
impact on pre-eclampsia and its complications. They should also
provide information about potential side-effects and adverse events
associated with antioxidants. Although most of the ongoing trials
are evaluating the combination of vitamin C and E, trials of other
antioxidant agents should not be initiated until there has been an
opportunity to assess the combined results of existing and currently
ongoing trials.
To date, no trials have reported on long-term outcome, for either
the women or the children. If antioxidants are shown to have an
overall beneficial effect in the short term, such long-term follow up
will become a priority, Where possible, currently recruiting trials
should collect information that would facilitate such follow up,
should it become necessary.
If, when all the currently ongoing trials have reported their re-
sults, it appears that antioxidants might be worthwhile for at least
some women, undertaking a review based on data from individual
women may help to determine who is most likely to benefit.
The ongoing trials are in: the United Kingdom (DAPIT:
david.mccance@royalhospitals.n-i.nhs.uk); the United States of
America (CAPPS: rsi-
jmr@mwri.magee.edu); Brazil (salvio˙freire@uol.com.br) and In-
dia, Peru, South Africa and Vietnam (VIP: WHO component;
merialdim@who.int or lucilla.poston@kcl.ac.uk); and Canada
(INTAPP: william.fraser@ogy.ulaval.ca), however, the INTAPP
trial has stopped recruiting women.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beazley 2002
Methods Treatment allocation: unclear, no methodological details given, women were “randomised”
Blinding of outcome assessment: “double blind” stated.
Documentation of exclusion: 9 (8%) women were lost to follow up
Use of placebo control: placebo control.
Participants 109 women between 14-20 weeks’ gestation and at “high risk of PE” including those with previous pre-
eclampsia, chronic hypertension, insulin requiring diabetes mellitus and multifetal gestation. Nil exclusion
criteria stated
Interventions Antioxidant: 1000 mg vitamin C and 400 IU vitamin E daily (n = 54).
Control: placebo, no further details (n = 55).
Outcomes 1. PE (not defined).
2. GA at delivery (mean, SD).
3. Preterm birth (< 37 weeks).
4. Birthweight (mean, SD).
5. Birthweight < 10 centile.
6. TAS and 8-IP.
Notes Criteria for subgroups:
risk of PE: mixed, by review criteria included both high and moderate/low risk.
GA at trial entry: 12-20 weeks’ gestation.
Antioxidant intake before trial entry: unclear.
Sample size calculation: none reported.
Compliance: no details of women’s compliance were given.
Location: United States of America.
Timeframe: unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Unclear risk B - Unclear
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Chappell 1999
Methods Treatment allocation: a computer-generated randomisation list using blocks of 10 was given to the hos-
pital pharmacy departments. Researchers allocated the next available number to participants and women
collected the trial tablets from the pharmacy department
Blinding of outcome assessment: double blind; women, caregivers and researchers were blinded to the
treatment allocation until recruitment, data collection and laboratory analyses were complete
Documentation of exclusion: pregnancy outcome data were reported for all women randomised (n = 283)
Use of placebo control: placebo control.
Participants 283 women between 16-22 weeks’ gestation with an abnormal Doppler waveform in either uterine artery
at 18-22 weeks’ gestation or a history in the preceding pregnancy of pre-eclampsia necessitating delivery
before 37 weeks’ gestation, eclampsia or HELLP syndrome.
Exclusion criteria: heparin or warfarin treatment, abnormal fetal-anomaly scan or multiple pregnancy.
1512 women underwent Doppler screening, 273 women had abnormal waveforms and of these, 242
women consented to the study. An additional 41 women who had a history of pre-eclampsia consented.
283 women were randomised, 72 women had normal Doppler scans at 24 weeks’ gestation and 24 women
did not return for a second scan and these women were withdrawn. A further 27 women withdrew from
the trial after 24 weeks’ gestation for various reasons. In total, 160 women completed the trial protocol
until delivery (n = 81 vitamin C and E group, n = 79 placebo group)
Interventions Antioxidant: 1000 mg vitamin C and 400 IU vitamin E daily (n = 141).
Control: placebo containing microcrystalline cellulose and soya bean oil, identical in appearance to the
vitamin C tablets and vitamin E capsules
Outcomes 1. Ratio of PAI-1 to PAI-2.
2. Incidence of PE (defined according to ISSHP guidelines).
3. Placental abruption.
4. Spontaneous preterm delivery (< 37 weeks).
5. Intrauterine death.
6. Small-for-gestational-age infants (on or below the 10th centile).
7. Mean systolic and diastolic blood pressure before delivery.
8. GA at delivery (median, IQR).
9. Birthweight (median, IQR).
10. Birthweight centile (median, IQR).
11. Mean plasma ascorbic acid and alpha-tocopherol concentrations during gestation.
12. Biochemical indices of oxidative stress and placental function
Notes Risk of PE: mixed, by review criteria included both high and moderate/low-risk women.
GA at trial entry: mixed. Between 16-22 weeks’ gestation.
Antioxidant intake before trial entry: unclear, not assessed.
Sample size calculation: the study had 80% power to detect a 30% reduction in PAI-1.
Compliance: not specifically reported. “Within the treated group, plasma ascorbic acid concentration
increased by 32% from baseline values and plasma alpha-tocopherol increased by 54%.”
Location: London, United Kingdom.
Timeframe: unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
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Chappell 1999 (Continued)
Allocation concealment Low risk A - Adequate
Han 1994
Methods Treatment allocation: women were “divided into two groups randomly”. No other methodological details
given
Blinding of outcome assessment: unclear, single blinded, but no information given on blinding of carers
or outcome assessors
Documentation of exclusion: none stated.
Use of placebo control: placebo stated but no details given.
Participants 100 women with “high-risk factors of PIH”.
No other information was provided about the participants, nil exclusion criteria stated
Interventions Antioxidant: 100 ug/d selenium, given as a “natural dietetic liquid containing 100 ug/d selenium for 6-8
weeks during late pregnancy” (n = 52).
Control: placebo, given in “the same manner” (n = 48).
Outcomes 1. Change in maternal and umbilical blood selenium level.
2. Change in systolic and diastolic blood pressure.
3. Incidence of PIH (not defined).
4. Incidence of gestational oedema.
5. Incidence of proteinuria.
6. Birthweight.
7. Side-effects as measured by changes in the blood and urine routine analysis and liver and renal function
Notes Risk of PE: unclear, therefore moderate/low risk. Author’s state women were at high risk but no details
given.
GA at trial entry: unclear. Women supplemented “during late pregnancy”.
Antioxidant intake before trial entry: unclear, no information provided. Blood selenium level was assessed
in women prior to starting the trial.
Sample size calculation: none reported.
Compliance: unclear, no information provided.
Location: China.
Timeframe: unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Unclear risk B - Unclear
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Mahdy 2004
Methods Treatment allocation: unclear, “randomised double-blind placebo controlled clinical trial” stated. No other
methodological details given
Blinding of outcome assessment: “double-blind” stated but no information given on blinding of carers or
outcome assessors
Documentation of exclusion: none stated.
Use of placebo control: placebo stated but no details given.
Participants 113 primigravid women in early mid trimester (before 16 weeks’ gestation).
No other information was provided about the participants, nil exclusion criteria stated
Interventions Antioxidant: red palm oil which includes a tocotrienol-rich fraction (TRF).No other information including
dosage was provided (n = 46).
Control: placebo, no other information given (n = 67).
Outcomes 1. PIH (not defined).
2. PE (not defined).
Notes Risk of PE: moderate/low risk.
GA at trial entry: mixed. Women supplemented before 16 weeks’ gestation.
Antioxidant intake before trial entry: unclear, no information provided.
Sample size calculation: none reported.
Compliance: unclear, no information provided.
Location: unclear.
Timeframe: unclear.
Published in abstract form only.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Unclear risk B - Unclear
Merchant 2005
Methods Treatment allocation: unclear, “randomisation followed a 2x2 factorial design” stated. No other method-
ological details given
Blinding of outcome assessment: “double-blind” stated; the participant, tablet dispenser and study physi-
cians were blinded
Documentation of exclusion: 123 (11.4%) women were excluded from the analysis, of which 41 had
hypertension at trial entry. Data were not available for a further 89 (8.2%) women
Use of placebo control: placebo stated but no details given.
Participants 1078 pregnant women between 12 and 27 weeks’ gestation, who were HIV-1 infected without WHO-
defined stage IV disease, resident of Dar-es-Salaam, Tanzania and intending to remain in the city for the
duration of the pregnancy and 1 year thereafter
Interventions There were 4 treatment arms.
Antioxidant: daily multivitamin which contained 500 mg vitamin C, 30 mg vitamin E, 20 mg thiamin,
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Merchant 2005 (Continued)
20 mg riboflavin, 20 mg B-6, 50 micrograms b-12, 0.8 mg folic acid) or daily multivitamin plus vitamin
A (30 mg beta-carotene + 5000 IU preformed vitamin A) or vitamin A alone (30 mg beta-carotene + 5000
IU preformed vitamin A).
Control: placebo.
Outcomes 1. Hypertension in pregnancy, defined as systolic blood pressure >= 140 mmHg or diastolic blood pressure
>= 90 mmHg at any time in pregnancy (women hypertensive at randomisation were excluded from the
analysis)
Notes Risk of PE: moderate/low-risk women.
GA at trial entry: mixed. Between 12-27 weeks’ gestation.
Antioxidant intake before trial entry: unclear, not assessed.
Sample size calculation: a sample size calculation for the risk of hypertension in pregnancywas not reported.
Compliance: based on counts of returned pills from the mean compliance in all treatment groups was 91%
(median 96%).
Location: Tanzania.
Timeframe: April 1995-1997.
The primary aim of the study was to assess the effect of vitamin supplementation on adverse birth outcomes
and mother-to-child transmission of HIV. Assessing hypertension in pregnancy was a secondary aim of
the study
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Unclear risk B - Unclear
Poston 2006
Methods Treatment allocation: computer-generated randomisation list blocked by centre in groups of 10 to 12
individuals (mean size 6.7) was given to a third party.Midwives randomised eligible women online, women
were allocated a locally stored treatment pack with a centre-specific and participant-specific number
Blinding of outcome assessment: double blind; women, caregivers and researchers were blinded to the
treatment allocation until after completion of the study
Documentation of exclusion: 2404 women were randomised, data for 2395 women (99.6%) were analysed
Use of placebo control: placebo control.
Participants 2395 women with a gestational age between 14+0 - 21+6 weeks and one or more of: pre-eclampsia in
the pregnancy preceding the index pregnancy, requiring delivery before 37 completed weeks’ gestation;
diagnosis of HELLP syndrome in any previous pregnancy at any stage of gestation; eclampsia in any
previous pregnancy at any stage of gestation; essential hypertension requiring medication, currently or
previously; maternal diastolic blood pressure of 90mmHg ormore before 20 weeks’ gestation in the current
pregnancy; type 1 or 2 diabetes, requiring insulin or oral hypoglycaemic therapy before the pregnancy;
antiphospholipid syndrome; chronic renal disease; multiple pregnancy; abnormal uterine artery Doppler
waveform (18-22 weeks’ gestation) or primiparity with a body-mass index of 30 kg/m2 or more at first
antenatal visit.
Exclusion criteria: women unable or unwilling to give written informed consent, being treatedwith warfarin
or taking vitamin supplements that contained a dose of vitamin C of 200 mg or more or vitamin E of 40
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Poston 2006 (Continued)
IU or more daily
Interventions Antioxidant: 1000 mg vitamin C and 400 IU vitamin E daily (n = 1196).
Control: placebo tablets containing microcrystalline cellulose and capsules containing sunflower seed oil,
identical in appearance and taste to the vitamin C tablets and vitamin E capsules (n = 1199)
Outcomes 1. Incidence and severity of PE (defined according to ISSHP guidelines).
2. Incidence and severity of gestational hypertension.
3. Low birthweight (< 2.5 kg).
4. Small-for-gestational age (reported as < 5th centile and < 10th centile).
5. Preterm birth (< 37 weeks’ gestation and < 34 weeks’ gestation).
6. Gestational age at delivery.
7. Use of healthcare resources.
8. Longitudinal biochemical indices.
The trial had a range of other prespecified maternal and neonatal outcomes
Notes Risk of PE: mixed, by review criteria included both high and moderate/low-risk women.
GA at trial entry: mixed. Between 14-21+6 weeks’ gestation.
Antioxidant intake before trial entry: unclear, not assessed.
Sample size calculation: the study had 90% power to detect a 30% relative reduction in pre-eclampsia,
25% reduction in low birthweight, and a 30% reduction in SGA.
Compliance: based on counts of returned pills from 2070 women, 80% of these women took at least 50%
of their tables, 65% took 80% or more, 32% took all their tablets and 6% took none. There we no great
differences in compliance between groups.
Location: United Kingdom.
Timeframe: 6th August 2003-27th June 2005.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Low risk A - Adequate
Rivas 2000
Methods Treatment allocation: unclear, women were “randomly divided into 2 subgroups”
Blinding of outcome assessment: “triple blind” stated. No other details given
Documentation of exclusion: none stated.
Use of placebo control: placebo control.
Participants 127 women less than 29 weeks’ gestation and with “high risk for PE”, including nulliparity, previous PE,
obesity, hypertension, less than 20 years old, diabetes, nephropathy, mean arterial pressure above of 85
mmHg, positive roll-over test, black race, family history of hypertension or PE, twin pregnancy and poor
socioeconomic conditions.
Exclusion criteria: unclear, none stated.
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Rivas 2000 (Continued)
Interventions Antioxidant: 500 mg vitamin C and 400 IU vitamin E per day, in addition to 1 g fish oil 3 times a day
and 100 mg aspirin 3 times a week (n = 63).
Control: placebo, given “at the same posology and presentation” (n = 64)
Outcomes 1. PE (not defined).
2. The authors report that “no serious maternal and neonatal side-effects of treatment occurred in either
group”, no other details were given
Notes Risk of PE: mixed, by review criteria included both high and moderate/low-risk women.
GA at trial entry: mixed. Women were < 29 weeks’ gestation.
Antioxidant intake before trial entry: unclear.
Sample size calculation: none stated.
Compliance: unclear, no information provided.
Location: Venezuela.
Timeframe: unclear.
Published in abstract format only.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Unclear risk B - Unclear
Rumbold 2006
Methods Treatment allocation: randomisation was performed through a central telephone randomisation service,
the randomisation schedule was stratified by collaborating centre and gestational age (< 18 weeks versus
18 weeks or more). Treatment packs were prepared by a researcher not involved in recruitment or clinical
care, packs were labelled with a unique study number and contained 4 sealed opaque white plastic bottles
of either vitamin C and vitamin E or placebo tablets
Blinding of outcome assessment: double blind; women, caregivers and researchers were blinded to the
treatment allocation until after completion of the study
Documentation of exclusion: 1877 were randomised, there were no losses to follow up. For the 4 pairs of
twins in the study, outcomes for 1 randomly selected infant in each twin pair were chosen, outcomes for
the other 4 infants were excluded from the analyses
Use of placebo control: placebo control.
Participants 1877 nulliparouswomenwith a singleton pregnancy between 14+0 and 21+6weeks’ gestation, with normal
blood pressure at first measurement in pregnancy and again at trial entry.
Exclusion criteria: knownmultiple pregnancy, known potential lethal fetal anomaly, known thrombophilia,
chronic renal failure, antihypertensive therapy, or specific contraindications to vitamin C or E therapy such
as haemochromatosis or anticoagulant therapy.
Women were advised not to take any other supplements although a multivitamin that provided a daily
intake of no more than 200 mg vitamin C or 50 IU vitamin was permitted
Interventions Antioxidant: 1000 mg vitamin C and 400 IU vitamin E daily (n = 935).
Control: placebo tablets containing microcrystalline cellulose identical in appearance and taste to the
vitamin C and E tablets (n = 942)
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Rumbold 2006 (Continued)
Outcomes 1.Death or serious outcomes in the infant (a compositemeasure of prespecified fetal andneonatal outcomes)
.
2. Pre-eclampsia (defined according to ASSHP criteria).
3. Small-for-gestational age (< 10th centile).
The trial also included a range of prespecified maternal and neonatal outcomes, including preterm birth
reported as < 37 weeks’ gestation, < 34 weeks’ gestation and < 28 weeks’ gestation
Notes Risk of PE: moderate/low-risk women.
GA at trial entry: mixed. Between 14-21+6 weeks’ gestation.
Antioxidant intake before trial entry: at trial entry 94% of women in both groups had an adequate intake
of vitamin C, 43% of women in both groups had an adequate intake of vitamin E.
Sample size calculation: the study had 80% power to detect a reduction in the risk of death or serious
outcomes in the infants from 6.5% to 3.7%, and a reduction in the risk of pre-eclampsia from 10.0 to 6.
3%.
Compliance: based on verbal recall from women, 66.9% of women in the vitamin group took 80% or
more of their tables, compared with 69.9% in the placebo group.
Location: Australia.
Timeframe: December 2001 to January 2005.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Low risk A - Adequate
Sharma 2003
Methods Treatment allocation: third-party randomisation using numbered opaque envelopes made up from com-
puter-generated numbers
Blinding of outcome assessment: women, caregivers, research staff and outcome assessors were blinded to
the treatment allocation
Documentation of exclusion: none.
Use of placebo control: placebo control.
Participants 251 primigravidas between 16-20 weeks with no medical complication such as renal disease, primary
hypertension, cardiovascular disease, diabetes or connective tissue disease.
Exclusion criteria: unclear, none stated.
Interventions Antioxidant: 2 mg lycopene twice daily (4 mg daily total) until delivery (n = 116).
Control: placebo, similar looking tablets of soya bean oil and bees wax (n = 135)
Outcomes 1. PE (defined according to ISSHP guidelines).
2. Eclampsia.
3. Mean diastolic blood pressure.
4. Intrauterine growth restriction (weight below the 10th centile for gestational age).
5. Mean fetal weight.
6. Mean gestation.
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Sharma 2003 (Continued)
Notes Risk of PE: moderate/low risk.
GA at trial entry: 12-20 weeks’ gestation.
Antioxidant intake before trial entry: not assessed.
Sample size calculation: stated as “considering the incidence of pre-eclampsia to be 7-10% in primigravidas,
and taking 5% as error, a sample size of approximately 124 women in each group was calculated”. The trial
planned to enrol 300 women (150 in each group) however staffing limitations resulted in the trial being
stopped after 251 women were recruited, leaving 116 women and 135 in each group.
Compliance: unclear, compliance was assessed by pill counts, but no other information provided.
Location: New Delhi, India.
Timeframe: unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Low risk A - Adequate
Steyn 2002
Methods Randomisation: third-party randomisation, Roche Pharmaceuticals supplied numbered containers with
either vitamin C or placebo tablets, and they retained the code until completion of the study
Blinding of outcome assessment: “double blind” stated, Roche Pharmaceuticals retained the code until
completion of the study
Documentation of exclusion: none reported.
Use of placebo control: placebo control.
Participants 200 women less than 26 weeks’ gestation and with a history of a previous mid-trimester abortion (sponta-
neous expulsion of the uterine contents between 13 and 26 weeks’ gestation) or previous preterm labour
(spontaneous onset of labour and delivery before 37 weeks’ gestation).
Exclusion criteria: womenwith previous preterm labour due to iatrogenic causes, such as previous induction
of labour before term for severe pre-eclampsia, or women with multiple pregnancies, proven cervical
incompetence or other known reasons for preterm labour were excluded.
203 consecutive women were invited to participate in the study, of which 200 consented
Interventions Antioxidant: 250 mg vitamin C twice daily (500 mg daily total) until 34 weeks’ gestation (n = 100).
Control: “exact matching” placebo, no other details given (n = 100).
Women attended for an antenatal visit every 2 weeks until 34 weeks’ gestation, and at each visit women
were tested for bacterial vaginosis.
Women who tested positive for Mycoplasma hominis at trial entry were treated with 500 mg erythromycin
6 hourly for 7 days, from 22 weeks’ gestation up until 32 weeks’ gestation
Outcomes 1. Preterm labour, defined as delivery before 37 completed weeks and subdivided into delivery < 34 weeks’
gestation and < 28 weeks’ gestation.
2. Gestational age at delivery (median and range).
3. Birthweight (median and range).
4. Miscarriage.
5. Intrauterine death.
6. Early and late neonatal death.
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Steyn 2002 (Continued)
7. Duration of neonatal hospitalisation.
8. Antepartum haemorrhage (including placental abruption).
9. PE.
10. Hypertension (not defined).
11. Induction of labour.
12. Bacterial vaginosis.
13. Leucocyte vitamin C levels at trial entry.
Notes Risk of PE: moderate/low risk, by review criteria.
GA at trial entry: mixed. Women were below 26 weeks’ gestation.
Antioxidant intake before trial entry: 11 women (5.5%) had a vitamin C intake less than 67% of the RDI
(70 mg), as assessed by a food frequency questionnaire.
Sample size calculation: none indicated.
The results presented are from an interim analysis performed by an independent panel after 100 women in
each group had delivered, which indicated “very few differences between the 2 groups. Further recruitment
will not have resulted in obtaining a significant difference”.
Compliance: no information provided.
Location: South Africa.
Timeframe: unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment Low risk A - Adequate
ASSHP: Australian Society for the Study of Hypertension in Pregnancy
GA: gestational age
HELLP: haemolysis, elevated liver enzymes and low platelets
IP: isoprostane
IQR: interquartile range
ISSHP: International Society for the Study of Hypertension in Pregnancy
IU: international units
PAI-1: plasminogen activator inhibitor-1
PAI-2: plasminogen activator inhibitor-2
PE: pre-eclampsia
PIH: pregnancy-induced hypertension
RDI: recommended daily intake
SD: standard deviation
SGA: small-for-gestational age
TAS: total antioxidant status
WHO: World Health Organization
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anthony 1996 Study design: randomised controlled trial.
Intervention: vitamin E supplementation (dose not stated).
Participants: 73 women undergoing conservative antenatal management of pre-eclampsia.
Outcomes: duration of conservative management, indications for delivery, renal function, protein excretion
and platelet levels.
Published as an abstract only.
Bolisetty 2002 Study design: pilot case control, not randomised.
Intervention: daily 20 mg beta-carotene, 167.8 mg vitamin E and 1000 mg vitamin C versus control.
Participants: 5 women at risk of preterm delivery between 30 and 36 weeks were supplemented and 7 women
of comparable gestation acted as controls.
Outcomes: biochemical assessments of oxidative stress and maternal plasma concentrations of beta-carotene,
vitamin E and vitamin C
Borna 2005 Study design: randomised controlled trial.
Intervention: daily 500 mg vitamin C and 400 IU vitamin E or placebo.
Participants: 60 women with a preterm premature rupture of membranes, a singleton pregnancy and between
26 and 34 weeks’ gestation.
Outcomes: chorioamnionitis, latency until delivery, gestational age at delivery, mode of delivery, birthweight,
early neonatal sepsis, respiratory distress syndrome, neonatal death and postpartum endometritis
Casanueva 2005 Study design: randomised controlled trial.
Intervention: daily 100 mg vitamin C or placebo.
Participants: 120 women with no acute or chronic diseases, < 20 weeks’ gestation, with a singleton pregnancy,
no consumption of vitamin supplements and providing informed written consent.
Outcomes: premature rupture of the chorioamniotic membranes and preterm labour
Chaudhuri 1969 Study design: quasi-randomised controlled trial.
Intervention: multivitamin containing vitamin C versus control (no supplement). 32% of participants were
excluded from the analyses.
Participants: women attending the antenatal clinic who were below 24 weeks’ gestation.
Outcomes: toxaemia (any, moderate and severe).
Dijkhuizen 2004 Study design: randomised controlled trial.
Intervention: daily 4.5 mg beta-carotene, 30 mg zinc or both or placebo. All women received daily 30 mg
iron and 0.4 mg folic acid.
Participants: 230women at <20weeks’ gestation.Twin pregnancies or congenital abnormalities that interfered
with growth, development, or metabolism were excluded.
Outcomes: micronutrient status at 1 and 6 months postpartum, preterm birth, birthweight, postnatal infant
anthropometric measures
Ferguson 1955 Study design: quasi-randomised controlled trial.
Intervention: daily 1 g methionine, 20 mg thiamine chloride, 10 mg riboflavin and 100 mg niacinamide or
placebo. Methionine is not considered to act directly as an antioxidant.
Participants: 436 women attending a ’Toxaemia Clinic’, at various stages in their pregnancy. 38% of women
were excluded.
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Outcomes: pre-eclampsia, superimposed pre-eclampsia, weight gain during pregnancy, eclampsia, abortions,
stillbirths, neonatal deaths, birthweight < 2500 grams and < 2300 grams
Gulmezoglu 1997 Study design: randomised controlled trial.
Intervention: daily 800 IU vitamin E, 1000 mg vitamin C and 200 mg allopurinol, or placebo.
Participants: 56 women with severe pre-eclampsia diagnosed between 24 and 32 weeks’ gestation at trial
entry.
Outcomes: prolongation of pregnancy, biochemical assessment of oxidative stress and antioxidants, maternal
complications, side-effects, infant outcomes and haematologic and renal parameters
Herrera 1993 Study design: randomised controlled trial.
Intervention: nutritional supplementation with soy proteins, linoleic acid and calcium or placebo. These
interventions are not considered to be antioxidants.
Participants: 74 normotensive women at 28-29 weeks’ gestation with eithermean blood pressure of 80mmHg
or higher and a positive roll-over test.
Outcomes: PIH, pre-eclampsia, gestational age at birth, caesarean section and fetal weight
Marya 1987 Study design: randomised controlled trial.
Intervention: calcium (375 mg/day) and vitamin D (1200 IU/day) versus control. Calcium and vitamin D
are not considered to be antioxidants.
Participants: 400 women between 20-24 weeks’ gestation.
Outcomes: systolic and diastolic blood pressure, incidence of toxaemia
Morrison 1984 Study design: randomised controlled trial.
Intervention: random allocation to the treatment or normal diet, where the treatment diet involved additional
linoleic acid.
Participants: 34 primigravid women with PIH.
Outcomes: diastolic blood pressure, birthweight, the “development of complications in PIH”.
Published in abstract form only.
Pawlowicz 2000 Study design: randomised controlled trial.
Intervention: anthocyanins derived from chokeberry or placebo.
Participants: 105 pregnant women with intrauterine growth restriction of idiopathic and pre-eclamptic origin
on the turn of the second trimester.
Outcomes: serum concentration of autoantibodies to oxidized low density lipoproteins. No clinically relevant
outcomes reported
People’s League 1942 Study design: quasi-randomised controlled trial.
Intervention: daily multivitamin preparation containing 100 mg vitamin C, ferrous iron 0.26 g, calcium 0.
26 g, minute quantities of iodine, manganese and copper, adsorbate of vitamin B1 containing all factors of
the B complex and halibut liver oil 0.36 g containing vitamin A (52,000 IU per g) and vitamin D (2500 IU
per g) or control (no placebo).
Participants: 5021 women <= 24 weeks’ gestation, attending the antenatal clinics and in ’good health’.
Outcomes: toxaemia (hypertension only, albuminuria with or without hypertension, or hypertension with
albuminuria),maternal sepsis, length of gestation, stillbirth, birthweight, neonatalmortality and breastfeeding
Powers 2000 Not a trial. This paper involves comment on the trial by Chappell and colleagues (Chappell 1999)
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Pressman 2003 Study design: randomised controlled trial.
Intervention: 500 mg vitamin C and 400 IU vitamin E daily.
Participants: pregnant women at 35 weeks’ gestation.
Outcomes: maternal plasma concentrations and amniotic fluid concentrations of vitamin C and E. No
relevant clinical outcomes reported
Radhika 2003 Study design: randomised controlled trial.
Intervention: daily sachets containing red palm oil (approximately 2400 micrograms beta-carotene) or
placebo.
Participants: 170 women between 16 and 24 weeks’ gestation.
Outcomes: maternal and neonatal vitamin A status, maternal anaemia, maternal weight gain, birthweight,
low birthweight (< 2.5 kg), gestational age at birth and preterm birth
Roes 2006 Study design: randomised controlled trial.
Intervention: 3, 600 mg oral N-acetylcysteine tablets every 8 hours or matching placebo until delivery.
Participants: 38 women with severe pre-eclampsia or HELLP syndrome, or both, a singleton pregnancy and
between 25 and 33 weeks’ gestation.
Outcome: treatment to delivery interval, biochemical assessment of glutathione and parameters of oxidative
stress
Sawhney 2000 Study design: randomised controlled trial.
Intervention: vitamin E supplementation (dose not reported) or no treatment.
Participants: 60 women with established pre-eclampsia.
Outcomes: lipid peroxide levels, alpha-tocopherol levels and pregnancy continuation > 14 days.
Published in abstract form only.
Sikkema 2002 Study design: randomised controlled trial.
Intervention: single dose of 2 grams vitamin C or placebo.
Participants: 18 women with established pre-eclampsia.
Outcome: flow mediated vasodilation.
Published in abstract form only.
Theobald 1937 Study design: quasi-randomised trial.
Intervention: daily 20 g calcium lactate, 11,000 IU vitamin A and 450 units vitamin D or control (no
placebo).
Participants: 100 ’apparently healthy’ women < 24 weeks’ gestation.
Outcomes: toxaemia (hypertension only, hypertension and albuminuria, albuminuria only) and ’other symp-
toms’ of pregnancy
Thomson 2001 Study design: unclear, randomisation not stated.
Intervention: daily 50 micrograms selenium (L-selenomethionine) or placebo during pregnancy and post-
partum.
Participants: 35 women in the ’earliest stages of pregnancy’ plus 17 non-pregnant women who received the
selenium, serving as ’positive controls’.
Outcomes: measures of selenium and iodine status, clearance and excretion; no pregnancy outcomes reported
West 1999 Study design: randomised controlled trial.
Intervention: weekly oral vitamin A (7000 micrograms retinol equivalents) or beta-carotene (42 mg, or 7000
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microgram retinol equivalents) or placebo given prior to, during and after pregnancy.
Participants: 44,646 women, of whom 20,119 became pregnant, 22,819 times. Data about ’symptoms of
illness’ in pregnancy available for 15,832 women.
Outcome: pregnancy-related mortality and a range of ’symptoms of illness’ in pregnancy. Pre-eclampsia/
eclampsia was reported but defined as “any swelling of hands/face or convulsions” at either < 12, 12-28, >
28 weeks’ gestation or postpartum. Blood pressure was assessed in a subset of women, for this subset, pre-
eclampsia defined as systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg plus any
swelling of hands/face or convulsions. Data are reported for the subset of women assessed for pre-eclampsia
after 20 weeks’ gestation (472/15,832, 2.99%). The rate of pre-eclampsia in each treatment group was: 7/
185 (3.78%), beta-carotene group; 3/152 (1.97%), vitamin A group and 6/135 (4.44%), placebo group.
Reason for exclusion: missing data for > 20% of participants
HELLP: haemolysis, elevated liver enzymes and low platelets
IU: international units
PIH: pregnancy induced hypertension
Characteristics of ongoing studies [ordered by study ID]
DAPIT 2004
Trial name or title The Diabetes and Pre-eclampsia Intervention Trial (DAPIT).
Clinical Trial Identifier: ISRCTN27214045
Methods
Participants Inclusion criteria:
type 1 diabetes preceding pregnancy; age >= 16 years; between 8 and 22 weeks’ gestation; date of last menstrual
period certain or ultrasound estimation from 6-22 weeks of gestational age is available, or both; singleton
pregnancy.
Exclusion criteria:
ingestion of preparations containing vitamin C > 500 mg/day or vitamin E > 200 IU/day; participation in
another study which may interfere with DAPIT; participation in DAPIT during a previous pregnancy, where
DAPIT trial medication was taken within the last 6 months; any notation of drug abuse: cocaine, LSD,
heroin, marijuana, inhaled solvents/gases; warfarin therapy.
Planned sample size: 945 women.
Interventions Daily 1000 mg vitamin C and 400 IU vitamin E or placebo.
Outcomes Primary outcome:
incidence of pre-eclampsia.
Secondary outcomes: endothelial activation, birthweight centile
Starting date April 2003.
Contact information Dr David R McCance
Consultant Physician/Honorary Senior Lecturer, Regional Centre for Endocrinology and Diabetes, Royal
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DAPIT 2004 (Continued)
Victoria Hospital, Belfast BT12 6BA.
E-mail: david.mccance@royalhospitals.n-i.nhs.uk
Notes
INTAPP 2005
Trial name or title International Trial of Antioxidants for the Prevention of Preeclampsia (INTAPP)
Methods
Participants Two stratum’s of participants:
1. nulliparous women without additional risk factors.
2. nulliparous women with at least 1 of the risk factors: diabetes, chronic hypertension, obesity, multiple
pregnancy, and for multiparous women, a past history of pre-eclampsia.
Planned sample size: 13,334 (stratum 1) and 3760 (stratum 2)
Interventions Daily 1000 mg vitamin C and 400 IU vitamin E or placebo.
Outcomes Frequency of pre-eclampsia, gestational hypertensionwith adverse conditions, intrauterine growth restriction,
preterm birth
Starting date January 2004.
On April 10th 2006, the INTAPP Steering Committee made a decision to stop the trial. At the time of this
decision, 2647 women had been recruited into the trial. The last INTAPP participant delivered in October
2006, the trial results are expected to be available in mid-2007
Contact information Prof W Fraser
Department of Obstetrics and Gynaecology, Laval University, Quebec, Canada.
E-mail: william.fraser@ogy.ulaval.ca
Notes
NICHD 2004
Trial name or title Antioxidant therapy to prevent preeclampsia.
Clinical Trial Identifier: NCT00097110
Methods
Participants Inclusion criteria: gestational age between 12+0-19+6 weeks; chronic hypertension or past history of pre-
eclampsia/eclampsia, and attendance at a participating hospital
Exclusion criteria:
planned delivery elsewhere; multifetal gestation; allergy to vitamin C or vitamin E; requirement for aspirin
or anticoagulant medication; proteinuria = 2+ on dipstick urine test, or proteinuria = 1+ on dipstick and
= 300 mg/24 hours; pre-pregnancy diabetes mellitus; known fetal anomaly incompatible with life; prior
participation in the study; unwillingness to take the study medication
Planned sample size: 734 women.
32Antioxidants for preventing pre-eclampsia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NICHD 2004 (Continued)
Interventions Daily 1000 mg vitamin C and 400 IU vitamin E or placebo until delivery
Outcomes Primary outcome: incidence of pre-eclampsia.
Secondary outcomes: severity of pre-eclampsia; incidence of gestational hypertension or pre-eclampsia; fre-
quency of abruptio placentae; incidence of preterm birth; small-for-gestational-age infant or low birthweight
infants; biomarker level correlation with pre-eclampsia
Starting date Enrolment: July 2003-October 2007.
Last follow up: April 2007. Data entry closure: July 2007.
Contact information Dr JA Spinnato
University of Cincinnati, The United States of America.
Dr Salvio Freire, Federal University of Pernambuco, Recife, Pernambuco.
E-mail: salvio freire@uol.com.br
Notes
NICHD MFMU Network
Trial name or title Combined Antioxidants and Preeclampsia Prediction Studies (CAPPS)
Methods
Participants Inclusion criteria: gestational age 9+0-16+6 weeks, singleton pregnancy, nulliparous,
BP < 135/85 mmHg, no antihypertensive medication/diuretics, proteinuria 0 or trace, no vitamin C or E >
amount in prenatal vitamins and with informed consent.
Planned sample size: 10,000 women.
Interventions Daily 1000 mg vitamin C and 400 IU vitamin E or placebo until delivery
Outcomes Primary outcomes:
BP > 160/110 mmHg or BP > 140/90 mmHg > 20 weeks’ and one of:
1. SGOT (AST) > 100 U/L.
2. Platelets < 100,000/mm3.
3. Creatinine > 1.5 mg/dL.
4. Eclampsia.
5. Fetal/neonatal death.
6. SGA < 3rd centile.
7. Preterm delivery < 32 weeks.
Starting date Enrolment: May 2003-April 2005.
Data collection: May 2003-March 2006.
Closeout/final analysis: April 2006-November 2006.
Contact information Prof JM Roberts
Director, Magee-Women’s Research Institute
Professor and Vice Chair (Research) of Obstetrics, Gynecology and Reproductive Sciences, University of
Pittsburgh.
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NICHD MFMU Network (Continued)
E-mail: rsijmr@mwri.magee.edu
Notes
VIP WHO Component
Trial name or title Vitamins in Preeclampsia (VIP): a multicentre randomised clinical trial of vitamin C and E supplementation
in pregnancy for the prevention of pre-eclampsia (India, Peru, Vietnam)
Clinical Trial Identifier: ISRCTN86677348
Methods
Participants Inclusion criteria:
gestational age between 14+0 - 21+6 weeks with 1 or more of the following risk factors: chronic hypertension
(diastolic bloodpressure (BP) >90mmHg); pre-gestational diabetes; arterial, venous or small vessel thrombosis
in any organ tissue; unexplained death of morphologically normal fetus at or beyond 10 weeks’ gestation;
premature births before 34weeks due to pre-eclampsia, eclampsia or severe placental insufficiency; unexplained
consecutive spontaneous abortions before 10 weeks; chronic renal disease; multiple pregnancy; past history
of pre-eclampsia, eclampsia or HELLP syndrome (haemolysis, elevated liver enzyme levels and low platelet
count)
Exclusion criteria:
inability to give informed consent; women taking supplements containing > 200 mg vitamin C or > 50 IU
vitamin E daily dose; women taking warfarin.
Planned sample size: 1700 women.
Interventions Daily 1000 mg vitamin C and 400 IU vitamin E or placebo until delivery
Outcomes Incidence of pre-eclampsia, birthweight centile (< 5th).
Starting date Unclear. Expected to be completed in 2006.
Contact information Dr M Merialdi
20, Avenue Appia,
Geneva-27, CH 1211, Switzerland
E-mail: merialdim@who.int
In conjunction with:
Prof L Poston
Director of Research Division of Reproductive Health, Endocrinology and Development (King’s College
London)
and Prof A Shennan,
Maternal and Fetal Research Unit
10th Floor North Wing
St Thomas’ Hospital
London SE1 7EH
E-mail: lucilla.poston@kcl.ac.uk or
andrew.shennan@kcl.ac.uk
Notes
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AST: aspartate aminotransferase
BP: blood pressure
HELLP: haemolysis, elevated liver enzymes and low platelets
IU: international units
SGA: small-for-gestational age
SGOT: serum glutamic-oxaloacetic transaminase
SLE: systemic lupus erythematosus
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D A T A A N D A N A L Y S E S
Comparison 1. Any antioxidants versus control or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pre-eclampsia 9 5446 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.51, 1.06]
2 Severe pre-eclampsia 2 2495 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.89, 1.76]
3 Preterm birth 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 < 37 weeks 5 5198 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.99, 1.22]
3.2 < 34 weeks 2 4651 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.98, 1.45]
3.3 < 28 weeks 2 2077 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.55, 2.06]
4 Small-for-gestational age 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 < 10th centile 5 5271 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.62, 1.11]
4.2 < 5th centile 1 2784 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.98, 1.32]
4.3 < 3rd centile 1 1853 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.38, 1.08]
5 Any baby death 4 5144 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.53]
6 Any baby death (subgrouped by
timing of death)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Miscarriage or stillbirth 4 5144 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.92, 1.90]
6.2 Neonatal death 3 4748 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.28, 1.23]
7 Maternal death 2 4272 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 16.01]
8 Gestational hypertension 7 5817 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.62, 1.26]
9 Severe hypertension 2 4272 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.85, 2.30]
10 Use of antiypertensives 2 4272 Risk Ratio (M-H, Fixed, 95% CI) 1.77 [1.22, 2.57]
10.1 Any antihypertensives 1 1877 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.03, 2.69]
10.2 Intravenous
antihypertensives
1 2395 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [1.07, 3.53]
11 Elective delivery (induction
of labour or elective caesarean
section)
2 2077 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.99, 1.25]
12 Caesarean section (emergency
plus elective)
1 1877 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.87, 1.18]
13 Bleeding episodes (including
placental abruption, APH,
PPH, need for transfusion)
3 2360 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.35, 4.68]
14 Serious maternal morbidity
(including eclampsia, liver and
renal failure, DIC, stroke)
3 4523 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.39, 3.81]
15 Gestational age at birth 3 3135 Mean Difference (IV, Random, 95% CI) 0.26 [-0.84, 1.36]
16 Birthweight 5 5089 Mean Difference (IV, Random, 95% CI) 14.60 [-61.99, 91.
18]
17 Apgar score at 5 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Low (< 7) 1 2784 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.92, 2.87]
17.2 Very low (< 4) 2 4651 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.41, 2.07]
18 Respiratory distress syndrome 2 4567 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.08, 2.85]
19 Chronic lung disease 1 1853 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.72]
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20 Neonatal bleeding episodes
(intraventricular haemorrhage
and periventricular
leukomalacia)
2 4637 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.29, 1.29]
21 Necrotising enterocolitis 2 4567 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.09, 13.15]
22 Retinopathy of prematurity 2 4567 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.31, 2.50]
23 Side-effects not sufficient to
stop supplementation
1 1745 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.11, 2.34]
23.1 Self-reported abdominal
pain in late pregnancy
1 1745 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.11, 2.34]
24 Use of health service resources
for the woman
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
24.1 Antenatal hospital
admission for hypertension
1 1877 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [1.00, 2.39]
24.2 Use of intensive care 1 2395 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.24, 1.87]
25 Length of stay in hospital -
antenatal admission
1 2395 Mean Difference (IV, Fixed, 95% CI) 1.0 [0.43, 1.57]
26 Use of health service resources
for the infant
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
26.1 Admission to special care
nursery/intensive care nursery
1 2714 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.95, 1.29]
26.2 Admission to the special
care nursery/intensive care
nursery for > 7 days
1 2714 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.92, 1.35]
26.3 Admission to neonatal
intensive care unit for > 4 days
1 1853 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.27, 1.37]
26.4 Use of mechanical
ventilation
2 4567 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.81, 1.46]
27 Length of stay in hospital -
neonatal
1 181 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.28, 2.88]
27.1 Studies with random
allocation
1 181 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.28, 2.88]
Comparison 2. Any antioxidants versus control or placebo (sensitivity analyses based on trial quality)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pre-eclampsia 5 5006 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.58, 1.16]
1.1 High-quality studies
(Allocation concealment = A,
blinding, < 3% exclusions and
use of placebo)
5 5006 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.58, 1.16]
2 Severe pre-eclampsia 1 2395 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.89, 1.79]
2.1 High-quality studies
(Allocation concealment = A,
blinding, < 3% exclusions and
use of placebo)
1 2395 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.89, 1.79]
3 Preterm birth (< 37 weeks) 4 5098 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.98, 1.22]
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3.1 High-quality studies
(Allocation concealment = A,
blinding, < 3% exclusions and
use of placebo)
4 5098 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.98, 1.22]
4 Small-for-gestational age 4 5171 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.63, 1.13]
4.1 High-quality studies
(Allocation concealment = A,
blinding, < 3% exclusions and
use of placebo)
4 5171 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.63, 1.13]
5 Any baby death 4 5144 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.53]
5.1 High-quality studies
(Allocation concealment = A,
blinding, < 3% exclusions and
use of placebo)
4 5144 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.53]
Comparison 3. Any antioxidants versus control or placebo (subgroups by risk status)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pre-eclampsia 9 5446 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.51, 1.06]
1.1 Moderate/low-risk women 4 2441 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.48, 1.51]
1.2 Moderate/high-risk
women
5 3005 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.29, 1.11]
2 Severe pre-eclampsia 2 2495 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.89, 1.76]
2.1 Moderate low-risk women 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Moderate/high-risk
women
2 2495 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.89, 1.76]
3 Preterm birth 5 5198 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.99, 1.22]
3.1 Moderate/low-risk women 2 2067 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.92, 1.48]
3.2 Moderate/high-risk
women
3 3131 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.97, 1.22]
4 Small-for-gestational-age infant 5 5271 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.62, 1.11]
4.1 Moderate/low-risk women 2 2104 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.42, 1.19]
4.2 Moderate/high-risk
women
3 3167 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.63, 1.34]
5 Any baby death 4 5144 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.53]
5.1 Moderate/low-risk women 2 2077 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.53, 1.51]
5.2 Moderate high-risk
women
2 3067 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.85, 1.90]
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Comparison 4. Any antioxidants versus control or placebo (subgroups by gestation at entry)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pre-eclampsia 9 5446 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.51, 1.06]
1.1 < 12 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 12 - 20 weeks 2 351 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.34, 1.20]
1.3 14 - 21+6 weeks 2 4272 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.86, 1.20]
1.4 < 16 weeks 1 113 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.07, 7.80]
1.5 16 - 22 weeks 1 283 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.24, 0.91]
1.6 < 26 weeks 1 200 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.21, 4.84]
1.7 < 29 weeks 1 127 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.01, 0.54]
1.8 21 - 28 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.9 > 28 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.10 Unclear - ”during late
pregnancy”
1 100 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.01, 1.86]
2 Severe pre-eclampsia 2 2495 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.89, 1.76]
2.1 12 - 20 weeks 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.23, 5.11]
2.2 14 - 21+6 weeks 1 2395 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.89, 1.79]
3 Preterm birth 5 5198 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.99, 1.22]
3.1 12 - 20 weeks 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.75, 2.31]
3.2 14 - 21+6 2 4615 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.95, 1.20]
3.3 16 - 22 weeks 1 283 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.38, 3.87]
3.4 < 26 weeks 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.03, 1.99]
4 Small-for-gestational age 5 5271 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.62, 1.11]
4.1 12 - 20 weeks 2 351 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.29, 0.87]
4.2 14 - 21+6 2 4637 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.81, 1.29]
4.3 16 - 22 weeks 1 283 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.50, 1.08]
5 Any baby death 4 5144 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.53]
5.1 14 - 21+6 2 4661 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.79, 1.61]
5.2 16 - 22 weeks 1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.49]
5.3 < 26 weeks 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.56, 2.51]
Comparison 5. Any antioxidants versus control or placebo (subgroups by antioxidant type)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pre-eclampsia 9 5446 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.51, 1.06]
1.1 Vitamin C and E alone 4 4655 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.68, 1.25]
1.2 Vitamin C and E with
other agents
1 127 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.01, 0.54]
1.3 Vitamin C alone 1 200 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.21, 4.84]
1.4 Lycopene 1 251 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.24, 0.97]
1.5 Red palm oil 1 113 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.07, 7.80]
1.6 Selenium 1 100 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.01, 1.86]
2 Severe pre-eclampsia 2 2495 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.89, 1.76]
2.1 Vitamin C and E alone 2 2495 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.89, 1.76]
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3 Preterm birth 5 5198 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.99, 1.22]
3.1 Vitamin C and E alone 4 4998 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.96, 1.20]
3.2 Vitamin C and E with
other agents
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Vitamin C alone 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.03, 1.99]
3.4 Lycopene 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Red palm oil 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Selenium 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Small-for-gestational age 5 5271 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.62, 1.11]
4.1 Vitamin C and E alone 4 5020 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.73, 1.19]
4.2 Vitamin C and E with
other agents
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Vitamin C alone 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Lycopene 1 251 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.29, 0.91]
4.5 Red palm oil 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Selenium 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Any baby death 4 5144 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.53]
5.1 Vitamin C and E alone 3 4944 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.78, 1.57]
5.2 Vitamin C and E with
other agents
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Vitamin C alone 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.56, 2.51]
5.4 Lycopene 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Red palm oil 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Selenium 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Any antioxidants versus control or placebo, Outcome 1 Pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 1 Pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beazley 2002 9/52 9/48 11.5 % 0.92 [ 0.40, 2.13 ]
Chappell 1999 11/141 24/142 14.6 % 0.46 [ 0.24, 0.91 ]
Han 1994 0/52 4/48 1.5 % 0.10 [ 0.01, 1.86 ]
Mahdy 2004 1/46 2/67 2.2 % 0.73 [ 0.07, 7.80 ]
Poston 2006 181/1196 187/1199 26.5 % 0.97 [ 0.80, 1.17 ]
Rivas 2000 1/63 14/64 3.0 % 0.07 [ 0.01, 0.54 ]
Rumbold 2006 56/935 47/942 21.9 % 1.20 [ 0.82, 1.75 ]
Sharma 2003 10/116 24/135 14.1 % 0.48 [ 0.24, 0.97 ]
Steyn 2002 3/100 3/100 4.6 % 1.00 [ 0.21, 4.84 ]
Total (95% CI) 2701 2745 100.0 % 0.73 [ 0.51, 1.06 ]
Total events: 272 (Antioxidant(s)), 314 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 18.20, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 1.67 (P = 0.095)
0.001 0.01 0.1 1 10 100 1000
Favours antioxidants Favours control
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Analysis 1.2. Comparison 1 Any antioxidants versus control or placebo, Outcome 2 Severe pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 2 Severe pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beazley 2002 3/48 3/52 5.1 % 1.08 [ 0.23, 5.11 ]
Poston 2006 68/1196 54/1199 94.9 % 1.26 [ 0.89, 1.79 ]
Total (95% CI) 1244 1251 100.0 % 1.25 [ 0.89, 1.76 ]
Total events: 71 (Antioxidant(s)), 57 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
0.1 0.2 0.5 1 2 5 10
Favours antioxidants Favours control
Analysis 1.3. Comparison 1 Any antioxidants versus control or placebo, Outcome 3 Preterm birth.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 3 Preterm birth
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 < 37 weeks
Beazley 2002 20/52 14/48 3.0 % 1.32 [ 0.75, 2.31 ]
Chappell 1999 6/141 5/142 1.0 % 1.21 [ 0.38, 3.87 ]
Poston 2006 400/1372 373/1376 76.0 % 1.08 [ 0.95, 1.21 ]
Rumbold 2006 64/932 63/935 12.8 % 1.02 [ 0.73, 1.43 ]
Steyn 2002 50/100 35/100 7.1 % 1.43 [ 1.03, 1.99 ]
Subtotal (95% CI) 2597 2601 100.0 % 1.10 [ 0.99, 1.22 ]
Total events: 540 (Antioxidant(s)), 490 (Control)
0.1 0.2 0.5 1 2 5 10
Favours antioxidants Favours control
(Continued . . . )
42Antioxidants for preventing pre-eclampsia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 3.14, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 < 34 weeks
Poston 2006 174/1393 144/1391 88.4 % 1.21 [ 0.98, 1.49 ]
Rumbold 2006 20/932 19/935 11.6 % 1.06 [ 0.57, 1.97 ]
Subtotal (95% CI) 2325 2326 100.0 % 1.19 [ 0.98, 1.45 ]
Total events: 194 (Antioxidant(s)), 163 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
3 < 28 weeks
Rumbold 2006 6/935 6/942 37.4 % 1.01 [ 0.33, 3.11 ]
Steyn 2002 11/100 10/100 62.6 % 1.10 [ 0.49, 2.47 ]
Subtotal (95% CI) 1035 1042 100.0 % 1.07 [ 0.55, 2.06 ]
Total events: 17 (Antioxidant(s)), 16 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 1.4. Comparison 1 Any antioxidants versus control or placebo, Outcome 4 Small-for-gestational
age.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 4 Small-for-gestational age
Study or subgroup Antioxidant Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 10th centile
Beazley 2002 2/52 4/48 1.9 % 0.46 [ 0.09, 2.41 ]
Chappell 1999 33/141 45/142 20.2 % 0.74 [ 0.50, 1.08 ]
Poston 2006 403/1393 360/1391 39.2 % 1.12 [ 0.99, 1.26 ]
Rumbold 2006 80/924 92/929 26.6 % 0.87 [ 0.66, 1.16 ]
Sharma 2003 14/116 32/135 12.0 % 0.51 [ 0.29, 0.91 ]
Subtotal (95% CI) 2626 2645 100.0 % 0.83 [ 0.62, 1.11 ]
Total events: 532 (Antioxidant), 533 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 12.54, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.26 (P = 0.21)
2 < 5th centile
Poston 2006 294/1393 259/1391 100.0 % 1.13 [ 0.98, 1.32 ]
Subtotal (95% CI) 1393 1391 100.0 % 1.13 [ 0.98, 1.32 ]
Total events: 294 (Antioxidant), 259 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
3 < 3rd centile
Rumbold 2006 23/924 36/929 100.0 % 0.64 [ 0.38, 1.08 ]
Subtotal (95% CI) 924 929 100.0 % 0.64 [ 0.38, 1.08 ]
Total events: 23 (Antioxidant), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
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Analysis 1.5. Comparison 1 Any antioxidants versus control or placebo, Outcome 5 Any baby death.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 5 Any baby death
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chappell 1999 1/141 2/142 2.9 % 0.50 [ 0.05, 5.49 ]
Poston 2006 51/1393 39/1391 56.6 % 1.31 [ 0.87, 1.97 ]
Rumbold 2006 12/935 17/942 24.6 % 0.71 [ 0.34, 1.48 ]
Steyn 2002 13/100 11/100 16.0 % 1.18 [ 0.56, 2.51 ]
Total (95% CI) 2569 2575 100.0 % 1.12 [ 0.81, 1.53 ]
Total events: 77 (Antioxidant(s)), 69 (Control)
Heterogeneity: Chi2 = 2.46, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 1.6. Comparison 1 Any antioxidants versus control or placebo, Outcome 6 Any baby death
(subgrouped by timing of death).
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 6 Any baby death (subgrouped by timing of death)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Miscarriage or stillbirth
Chappell 1999 1/141 2/142 4.0 % 0.50 [ 0.05, 5.49 ]
Poston 2006 43/1393 27/1391 54.1 % 1.59 [ 0.99, 2.56 ]
Rumbold 2006 11/935 13/942 25.9 % 0.85 [ 0.38, 1.89 ]
Steyn 2002 11/100 8/100 16.0 % 1.38 [ 0.58, 3.27 ]
Subtotal (95% CI) 2569 2575 100.0 % 1.32 [ 0.92, 1.90 ]
Total events: 66 (Antioxidant(s)), 50 (Control)
Heterogeneity: Chi2 = 2.38, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Neonatal death
Poston 2006 8/1350 12/1364 63.2 % 0.67 [ 0.28, 1.64 ]
Rumbold 2006 1/924 4/929 21.1 % 0.25 [ 0.03, 2.24 ]
Steyn 2002 2/89 3/92 15.6 % 0.69 [ 0.12, 4.03 ]
Subtotal (95% CI) 2363 2385 100.0 % 0.59 [ 0.28, 1.23 ]
Total events: 11 (Antioxidant(s)), 19 (Control)
Heterogeneity: Chi2 = 0.70, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 1.7. Comparison 1 Any antioxidants versus control or placebo, Outcome 7 Maternal death.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 7 Maternal death
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poston 2006 1/1196 1/1199 100.0 % 1.00 [ 0.06, 16.01 ]
Rumbold 2006 0/935 0/942 Not estimable
Total (95% CI) 2131 2141 100.0 % 1.00 [ 0.06, 16.01 ]
Total events: 1 (Antioxidant(s)), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
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Analysis 1.8. Comparison 1 Any antioxidants versus control or placebo, Outcome 8 Gestational
hypertension.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 8 Gestational hypertension
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chappell 1999 5/131 13/135 8.6 % 0.40 [ 0.15, 1.08 ]
Han 1994 4/52 11/48 7.8 % 0.34 [ 0.11, 0.98 ]
Mahdy 2004 3/46 7/67 5.9 % 0.62 [ 0.17, 2.29 ]
Merchant 2005 62/661 27/205 19.7 % 0.71 [ 0.47, 1.09 ]
Poston 2006 84/1196 55/1199 22.2 % 1.53 [ 1.10, 2.13 ]
Rumbold 2006 124/935 109/942 24.4 % 1.15 [ 0.90, 1.46 ]
Steyn 2002 11/100 10/100 11.3 % 1.10 [ 0.49, 2.47 ]
Total (95% CI) 3121 2696 100.0 % 0.89 [ 0.62, 1.26 ]
Total events: 293 (Antioxidant(s)), 232 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 17.27, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 1.9. Comparison 1 Any antioxidants versus control or placebo, Outcome 9 Severe hypertension.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 9 Severe hypertension
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poston 2006 7/1196 5/1199 19.3 % 1.40 [ 0.45, 4.41 ]
Rumbold 2006 29/935 21/942 80.7 % 1.39 [ 0.80, 2.42 ]
Total (95% CI) 2131 2141 100.0 % 1.39 [ 0.85, 2.30 ]
Total events: 36 (Antioxidant(s)), 26 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 1.10. Comparison 1 Any antioxidants versus control or placebo, Outcome 10 Use of
antiypertensives.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 10 Use of antiypertensives
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any antihypertensives
Rumbold 2006 43/935 26/942 61.8 % 1.67 [ 1.03, 2.69 ]
Subtotal (95% CI) 935 942 61.8 % 1.67 [ 1.03, 2.69 ]
Total events: 43 (Antioxidant(s)), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.036)
2 Intravenous antihypertensives
Poston 2006 31/1196 16/1199 38.2 % 1.94 [ 1.07, 3.53 ]
Subtotal (95% CI) 1196 1199 38.2 % 1.94 [ 1.07, 3.53 ]
Total events: 31 (Antioxidant(s)), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
Total (95% CI) 2131 2141 100.0 % 1.77 [ 1.22, 2.57 ]
Total events: 74 (Antioxidant(s)), 42 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
0.1 0.2 0.5 1 2 5 10
Favours antioxidants Favours control
50Antioxidants for preventing pre-eclampsia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.11. Comparison 1 Any antioxidants versus control or placebo, Outcome 11 Elective delivery
(induction of labour or elective caesarean section).
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 11 Elective delivery (induction of labour or elective caesarean section)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beazley 2002 6/100 3/100 0.9 % 2.00 [ 0.51, 7.78 ]
Rumbold 2006 370/935 338/942 99.1 % 1.10 [ 0.98, 1.24 ]
Total (95% CI) 1035 1042 100.0 % 1.11 [ 0.99, 1.25 ]
Total events: 376 (Antioxidant(s)), 341 (Control)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
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Analysis 1.12. Comparison 1 Any antioxidants versus control or placebo, Outcome 12 Caesarean section
(emergency plus elective).
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 12 Caesarean section (emergency plus elective)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rumbold 2006 250/935 248/942 100.0 % 1.02 [ 0.87, 1.18 ]
Total (95% CI) 935 942 100.0 % 1.02 [ 0.87, 1.18 ]
Total events: 250 (Antioxidant(s)), 248 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 1.13. Comparison 1 Any antioxidants versus control or placebo, Outcome 13 Bleeding episodes
(including placental abruption, APH, PPH, need for transfusion).
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 13 Bleeding episodes (including placental abruption, APH, PPH, need for transfusion)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chappell 1999 1/141 3/142 21.3 % 0.34 [ 0.04, 3.19 ]
Rumbold 2006 30/935 29/942 55.1 % 1.04 [ 0.63, 1.72 ]
Steyn 2002 7/100 1/100 23.6 % 7.00 [ 0.88, 55.86 ]
Total (95% CI) 1176 1184 100.0 % 1.28 [ 0.35, 4.68 ]
Total events: 38 (Antioxidant(s)), 33 (Control)
Heterogeneity: Tau2 = 0.73; Chi2 = 4.22, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.38 (P = 0.71)
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Analysis 1.14. Comparison 1 Any antioxidants versus control or placebo, Outcome 14 Serious maternal
morbidity (including eclampsia, liver and renal failure, DIC, stroke).
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 14 Serious maternal morbidity (including eclampsia, liver and renal failure, DIC, stroke)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poston 2006 4/1196 3/1199 55.7 % 1.34 [ 0.30, 5.96 ]
Rumbold 2006 2/935 1/942 18.5 % 2.01 [ 0.18, 22.18 ]
Sharma 2003 0/116 1/135 25.8 % 0.39 [ 0.02, 9.42 ]
Total (95% CI) 2247 2276 100.0 % 1.22 [ 0.39, 3.81 ]
Total events: 6 (Antioxidant(s)), 5 (Control)
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
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Analysis 1.15. Comparison 1 Any antioxidants versus control or placebo, Outcome 15 Gestational age at
birth.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 15 Gestational age at birth
Study or subgroup Antioxidant(s) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Beazley 2002 52 36.8 (3.6) 48 37.2 (3.9) 23.3 % -0.40 [ -1.87, 1.07 ]
Poston 2006 1393 37.4 (3.9) 1391 37.6 (3.7) 39.2 % -0.20 [ -0.48, 0.08 ]
Sharma 2003 116 37.72 (1.61) 135 36.56 (2.2) 37.5 % 1.16 [ 0.69, 1.63 ]
Total (95% CI) 1561 1574 100.0 % 0.26 [ -0.84, 1.36 ]
Heterogeneity: Tau2 = 0.78; Chi2 = 23.96, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.47 (P = 0.64)
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Analysis 1.16. Comparison 1 Any antioxidants versus control or placebo, Outcome 16 Birthweight.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 16 Birthweight
Study or subgroup Antioxidant(s) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Beazley 2002 52 2911 (901) 48 3050 (1021) 3.7 % -139.00 [ -517.68, 239.68 ]
Han 1994 52 3319 (407) 48 3189 (440) 13.4 % 130.00 [ -36.53, 296.53 ]
Poston 2006 1385 2901 (891) 1386 2976 (873) 28.7 % -75.00 [ -140.68, -9.32 ]
Rumbold 2006 932 3392 (599) 935 3386 (584) 30.9 % 6.00 [ -47.67, 59.67 ]
Sharma 2003 116 2751.17 (315.76) 135 2657.26 (444.3) 23.4 % 93.91 [ -0.53, 188.35 ]
Total (95% CI) 2537 2552 100.0 % 14.60 [ -61.99, 91.18 ]
Heterogeneity: Tau2 = 4199.43; Chi2 = 11.71, df = 4 (P = 0.02); I2 =66%
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 1.17. Comparison 1 Any antioxidants versus control or placebo, Outcome 17 Apgar score at 5
minutes.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 17 Apgar score at 5 minutes
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low (< 7)
Poston 2006 31/1393 19/1391 100.0 % 1.63 [ 0.92, 2.87 ]
Subtotal (95% CI) 1393 1391 100.0 % 1.63 [ 0.92, 2.87 ]
Total events: 31 (Antioxidant(s)), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
2 Very low (< 4)
Poston 2006 8/1393 9/1391 75.0 % 0.89 [ 0.34, 2.29 ]
Rumbold 2006 3/932 3/935 25.0 % 1.00 [ 0.20, 4.96 ]
Subtotal (95% CI) 2325 2326 100.0 % 0.92 [ 0.41, 2.07 ]
Total events: 11 (Antioxidant(s)), 12 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
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Analysis 1.18. Comparison 1 Any antioxidants versus control or placebo, Outcome 18 Respiratory distress
syndrome.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 18 Respiratory distress syndrome
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Poston 2006 91/1350 89/1364 58.3 % 1.03 [ 0.78, 1.37 ]
Rumbold 2006 2/924 12/929 41.7 % 0.17 [ 0.04, 0.75 ]
Total (95% CI) 2274 2293 100.0 % 0.48 [ 0.08, 2.85 ]
Total events: 93 (Antioxidant(s)), 101 (Control)
Heterogeneity: Tau2 = 1.38; Chi2 = 5.59, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.80 (P = 0.42)
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Analysis 1.19. Comparison 1 Any antioxidants versus control or placebo, Outcome 19 Chronic lung disease.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 19 Chronic lung disease
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rumbold 2006 1/924 5/929 100.0 % 0.20 [ 0.02, 1.72 ]
Total (95% CI) 924 929 100.0 % 0.20 [ 0.02, 1.72 ]
Total events: 1 (Antioxidant(s)), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
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Analysis 1.20. Comparison 1 Any antioxidants versus control or placebo, Outcome 20 Neonatal bleeding
episodes (intraventricular haemorrhage and periventricular leukomalacia).
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 20 Neonatal bleeding episodes (intraventricular haemorrhage and periventricular leukomalacia)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poston 2006 10/1393 16/1391 88.9 % 0.62 [ 0.28, 1.37 ]
Rumbold 2006 1/924 2/929 11.1 % 0.50 [ 0.05, 5.53 ]
Total (95% CI) 2317 2320 100.0 % 0.61 [ 0.29, 1.29 ]
Total events: 11 (Antioxidant(s)), 18 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
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Analysis 1.21. Comparison 1 Any antioxidants versus control or placebo, Outcome 21 Necrotising
enterocolitis.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 21 Necrotising enterocolitis
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Poston 2006 11/1350 4/1364 64.7 % 2.78 [ 0.89, 8.70 ]
Rumbold 2006 0/924 2/929 35.3 % 0.20 [ 0.01, 4.18 ]
Total (95% CI) 2274 2293 100.0 % 1.10 [ 0.09, 13.15 ]
Total events: 11 (Antioxidant(s)), 6 (Control)
Heterogeneity: Tau2 = 2.14; Chi2 = 2.56, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.07 (P = 0.94)
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Analysis 1.22. Comparison 1 Any antioxidants versus control or placebo, Outcome 22 Retinopathy of
prematurity.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 22 Retinopathy of prematurity
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poston 2006 6/1350 6/1364 80.0 % 1.01 [ 0.33, 3.12 ]
Rumbold 2006 0/924 1/929 20.0 % 0.34 [ 0.01, 8.22 ]
Total (95% CI) 2274 2293 100.0 % 0.88 [ 0.31, 2.50 ]
Total events: 6 (Antioxidant(s)), 7 (Control)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
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Analysis 1.23. Comparison 1 Any antioxidants versus control or placebo, Outcome 23 Side-effects not
sufficient to stop supplementation.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 23 Side-effects not sufficient to stop supplementation
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Self-reported abdominal pain in late pregnancy
Rumbold 2006 68/875 42/870 100.0 % 1.61 [ 1.11, 2.34 ]
Total (95% CI) 875 870 100.0 % 1.61 [ 1.11, 2.34 ]
Total events: 68 (Antioxidant(s)), 42 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
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Analysis 1.24. Comparison 1 Any antioxidants versus control or placebo, Outcome 24 Use of health service
resources for the woman.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 24 Use of health service resources for the woman
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antenatal hospital admission for hypertension
Rumbold 2006 49/935 32/942 100.0 % 1.54 [ 1.00, 2.39 ]
Subtotal (95% CI) 935 942 100.0 % 1.54 [ 1.00, 2.39 ]
Total events: 49 (Antioxidant(s)), 32 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
2 Use of intensive care
Poston 2006 6/1196 9/1199 100.0 % 0.67 [ 0.24, 1.87 ]
Subtotal (95% CI) 1196 1199 100.0 % 0.67 [ 0.24, 1.87 ]
Total events: 6 (Antioxidant(s)), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 1.25. Comparison 1 Any antioxidants versus control or placebo, Outcome 25 Length of stay in
hospital - antenatal admission.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 25 Length of stay in hospital - antenatal admission
Study or subgroup Antioxidant(s) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Poston 2006 1196 7 (8) 1199 6 (6) 100.0 % 1.00 [ 0.43, 1.57 ]
Total (95% CI) 1196 1199 100.0 % 1.00 [ 0.43, 1.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00054)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Any antioxidants versus control or placebo, Outcome 26 Use of health service
resources for the infant.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 26 Use of health service resources for the infant
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Admission to special care nursery/intensive care nursery
Poston 2006 280/1350 255/1364 100.0 % 1.11 [ 0.95, 1.29 ]
Subtotal (95% CI) 1350 1364 100.0 % 1.11 [ 0.95, 1.29 ]
Total events: 280 (Antioxidant(s)), 255 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
2 Admission to the special care nursery/intensive care nursery for > 7 days
Poston 2006 193/1350 175/1364 100.0 % 1.11 [ 0.92, 1.35 ]
Subtotal (95% CI) 1350 1364 100.0 % 1.11 [ 0.92, 1.35 ]
Total events: 193 (Antioxidant(s)), 175 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.26)
3 Admission to neonatal intensive care unit for > 4 days
Rumbold 2006 9/924 15/929 100.0 % 0.60 [ 0.27, 1.37 ]
Subtotal (95% CI) 924 929 100.0 % 0.60 [ 0.27, 1.37 ]
Total events: 9 (Antioxidant(s)), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
4 Use of mechanical ventilation
Poston 2006 74/1350 58/1364 71.6 % 1.29 [ 0.92, 1.80 ]
Rumbold 2006 13/924 23/929 28.4 % 0.57 [ 0.29, 1.11 ]
Subtotal (95% CI) 2274 2293 100.0 % 1.08 [ 0.81, 1.46 ]
Total events: 87 (Antioxidant(s)), 81 (Control)
Heterogeneity: Chi2 = 4.55, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.53 (P = 0.59)
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Analysis 1.27. Comparison 1 Any antioxidants versus control or placebo, Outcome 27 Length of stay in
hospital - neonatal.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 1 Any antioxidants versus control or placebo
Outcome: 27 Length of stay in hospital - neonatal
Study or subgroup Antioxidant(s) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Studies with random allocation
Steyn 2002 89 3.64 (5.6) 92 2.34 (5.2) 100.0 % 1.30 [ -0.28, 2.88 ]
Total (95% CI) 89 92 100.0 % 1.30 [ -0.28, 2.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial
quality), Outcome 1 Pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial quality)
Outcome: 1 Pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-quality studies (Allocation concealment = A, blinding, < 3% exclusions and use of placebo)
Chappell 1999 11/141 24/142 16.1 % 0.46 [ 0.24, 0.91 ]
Poston 2006 181/1196 187/1199 36.5 % 0.97 [ 0.80, 1.17 ]
Rumbold 2006 56/935 47/942 27.6 % 1.20 [ 0.82, 1.75 ]
Sharma 2003 10/116 24/135 15.5 % 0.48 [ 0.24, 0.97 ]
Steyn 2002 3/100 3/100 4.3 % 1.00 [ 0.21, 4.84 ]
Total (95% CI) 2488 2518 100.0 % 0.82 [ 0.58, 1.16 ]
Total events: 261 (Antioxidant(s)), 285 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 9.49, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 1.11 (P = 0.27)
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Analysis 2.2. Comparison 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial
quality), Outcome 2 Severe pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial quality)
Outcome: 2 Severe pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High-quality studies (Allocation concealment = A, blinding, < 3% exclusions and use of placebo)
Poston 2006 68/1196 54/1199 100.0 % 1.26 [ 0.89, 1.79 ]
Total (95% CI) 1196 1199 100.0 % 1.26 [ 0.89, 1.79 ]
Total events: 68 (Antioxidant(s)), 54 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
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Analysis 2.3. Comparison 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial
quality), Outcome 3 Preterm birth (< 37 weeks).
Review: Antioxidants for preventing pre-eclampsia
Comparison: 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial quality)
Outcome: 3 Preterm birth (< 37 weeks)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High-quality studies (Allocation concealment = A, blinding, < 3% exclusions and use of placebo)
Chappell 1999 6/141 5/142 1.0 % 1.21 [ 0.38, 3.87 ]
Poston 2006 400/1372 373/1376 78.4 % 1.08 [ 0.95, 1.21 ]
Rumbold 2006 64/932 63/935 13.2 % 1.02 [ 0.73, 1.43 ]
Steyn 2002 50/100 35/100 7.4 % 1.43 [ 1.03, 1.99 ]
Total (95% CI) 2545 2553 100.0 % 1.10 [ 0.98, 1.22 ]
Total events: 520 (Antioxidant(s)), 476 (Control)
Heterogeneity: Chi2 = 2.76, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.094)
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Analysis 2.4. Comparison 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial
quality), Outcome 4 Small-for-gestational age.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial quality)
Outcome: 4 Small-for-gestational age
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-quality studies (Allocation concealment = A, blinding, < 3% exclusions and use of placebo)
Chappell 1999 33/141 45/142 22.7 % 0.74 [ 0.50, 1.08 ]
Poston 2006 403/1393 360/1391 34.6 % 1.12 [ 0.99, 1.26 ]
Rumbold 2006 80/924 92/929 27.4 % 0.87 [ 0.66, 1.16 ]
Sharma 2003 14/116 32/135 15.3 % 0.51 [ 0.29, 0.91 ]
Total (95% CI) 2574 2597 100.0 % 0.84 [ 0.63, 1.13 ]
Total events: 530 (Antioxidant(s)), 529 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 11.65, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 2.5. Comparison 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial
quality), Outcome 5 Any baby death.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 2 Any antioxidants versus control or placebo (sensitivity analyses based on trial quality)
Outcome: 5 Any baby death
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High-quality studies (Allocation concealment = A, blinding, < 3% exclusions and use of placebo)
Chappell 1999 1/141 2/142 2.9 % 0.50 [ 0.05, 5.49 ]
Poston 2006 51/1393 39/1391 56.6 % 1.31 [ 0.87, 1.97 ]
Rumbold 2006 12/935 17/942 24.6 % 0.71 [ 0.34, 1.48 ]
Steyn 2002 13/100 11/100 16.0 % 1.18 [ 0.56, 2.51 ]
Total (95% CI) 2569 2575 100.0 % 1.12 [ 0.81, 1.53 ]
Total events: 77 (Antioxidant(s)), 69 (Control)
Heterogeneity: Chi2 = 2.46, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 3.1. Comparison 3 Any antioxidants versus control or placebo (subgroups by risk status), Outcome
1 Pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 3 Any antioxidants versus control or placebo (subgroups by risk status)
Outcome: 1 Pre-eclampsia
Study or subgroup Antioxidants Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Moderate/low-risk women
Mahdy 2004 1/46 2/67 2.2 % 0.73 [ 0.07, 7.80 ]
Rumbold 2006 56/935 47/942 21.9 % 1.20 [ 0.82, 1.75 ]
Sharma 2003 10/116 24/135 14.1 % 0.48 [ 0.24, 0.97 ]
Steyn 2002 3/100 3/100 4.6 % 1.00 [ 0.21, 4.84 ]
Subtotal (95% CI) 1197 1244 42.9 % 0.85 [ 0.48, 1.51 ]
Total events: 70 (Antioxidants), 76 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 5.11, df = 3 (P = 0.16); I2 =41%
Test for overall effect: Z = 0.56 (P = 0.57)
2 Moderate/high-risk women
Beazley 2002 9/52 9/48 11.5 % 0.92 [ 0.40, 2.13 ]
Chappell 1999 11/141 24/142 14.6 % 0.46 [ 0.24, 0.91 ]
Han 1994 0/52 4/48 1.5 % 0.10 [ 0.01, 1.86 ]
Poston 2006 181/1196 187/1199 26.5 % 0.97 [ 0.80, 1.17 ]
Rivas 2000 1/63 14/64 3.0 % 0.07 [ 0.01, 0.54 ]
Subtotal (95% CI) 1504 1501 57.1 % 0.56 [ 0.29, 1.11 ]
Total events: 202 (Antioxidants), 238 (Control)
Heterogeneity: Tau2 = 0.32; Chi2 = 12.99, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 2701 2745 100.0 % 0.73 [ 0.51, 1.06 ]
Total events: 272 (Antioxidants), 314 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 18.20, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 1.67 (P = 0.095)
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Analysis 3.2. Comparison 3 Any antioxidants versus control or placebo (subgroups by risk status), Outcome
2 Severe pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 3 Any antioxidants versus control or placebo (subgroups by risk status)
Outcome: 2 Severe pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Moderate low-risk women
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Moderate/high-risk women
Beazley 2002 3/48 3/52 5.1 % 1.08 [ 0.23, 5.11 ]
Poston 2006 68/1196 54/1199 94.9 % 1.26 [ 0.89, 1.79 ]
Subtotal (95% CI) 1244 1251 100.0 % 1.25 [ 0.89, 1.76 ]
Total events: 71 (Antioxidant(s)), 57 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 1244 1251 100.0 % 1.25 [ 0.89, 1.76 ]
Total events: 71 (Antioxidant(s)), 57 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 3.3. Comparison 3 Any antioxidants versus control or placebo (subgroups by risk status), Outcome
3 Preterm birth.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 3 Any antioxidants versus control or placebo (subgroups by risk status)
Outcome: 3 Preterm birth
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Moderate/low-risk women
Rumbold 2006 64/932 63/935 12.8 % 1.02 [ 0.73, 1.43 ]
Steyn 2002 50/100 35/100 7.1 % 1.43 [ 1.03, 1.99 ]
Subtotal (95% CI) 1032 1035 20.0 % 1.17 [ 0.92, 1.48 ]
Total events: 114 (Antioxidant(s)), 98 (Control)
Heterogeneity: Chi2 = 2.06, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Moderate/high-risk women
Beazley 2002 20/52 14/48 3.0 % 1.32 [ 0.75, 2.31 ]
Chappell 1999 6/141 5/142 1.0 % 1.21 [ 0.38, 3.87 ]
Poston 2006 400/1372 373/1376 76.0 % 1.08 [ 0.95, 1.21 ]
Subtotal (95% CI) 1565 1566 80.0 % 1.09 [ 0.97, 1.22 ]
Total events: 426 (Antioxidant(s)), 392 (Control)
Heterogeneity: Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 2597 2601 100.0 % 1.10 [ 0.99, 1.22 ]
Total events: 540 (Antioxidant(s)), 490 (Control)
Heterogeneity: Chi2 = 3.14, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
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Analysis 3.4. Comparison 3 Any antioxidants versus control or placebo (subgroups by risk status), Outcome
4 Small-for-gestational-age infant.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 3 Any antioxidants versus control or placebo (subgroups by risk status)
Outcome: 4 Small-for-gestational-age infant
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Moderate/low-risk women
Rumbold 2006 80/924 92/929 26.6 % 0.87 [ 0.66, 1.16 ]
Sharma 2003 14/116 32/135 14.7 % 0.51 [ 0.29, 0.91 ]
Subtotal (95% CI) 1040 1064 41.4 % 0.71 [ 0.42, 1.19 ]
Total events: 94 (Antioxidant(s)), 124 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.71, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.31 (P = 0.19)
2 Moderate/high-risk women
Beazley 2002 2/52 4/48 2.8 % 0.46 [ 0.09, 2.41 ]
Chappell 1999 33/141 45/142 22.0 % 0.74 [ 0.50, 1.08 ]
Poston 2006 403/1393 360/1391 33.9 % 1.12 [ 0.99, 1.26 ]
Subtotal (95% CI) 1586 1581 58.6 % 0.92 [ 0.63, 1.34 ]
Total events: 438 (Antioxidant(s)), 409 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 5.08, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 2626 2645 100.0 % 0.83 [ 0.62, 1.11 ]
Total events: 532 (Antioxidant(s)), 533 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 12.54, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.26 (P = 0.21)
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Analysis 3.5. Comparison 3 Any antioxidants versus control or placebo (subgroups by risk status), Outcome
5 Any baby death.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 3 Any antioxidants versus control or placebo (subgroups by risk status)
Outcome: 5 Any baby death
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Moderate/low-risk women
Rumbold 2006 12/935 17/942 24.6 % 0.71 [ 0.34, 1.48 ]
Steyn 2002 13/100 11/100 16.0 % 1.18 [ 0.56, 2.51 ]
Subtotal (95% CI) 1035 1042 40.5 % 0.90 [ 0.53, 1.51 ]
Total events: 25 (Antioxidant(s)), 28 (Control)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Moderate high-risk women
Chappell 1999 1/141 2/142 2.9 % 0.50 [ 0.05, 5.49 ]
Poston 2006 51/1393 39/1391 56.6 % 1.31 [ 0.87, 1.97 ]
Subtotal (95% CI) 1534 1533 59.5 % 1.27 [ 0.85, 1.90 ]
Total events: 52 (Antioxidant(s)), 41 (Control)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 2569 2575 100.0 % 1.12 [ 0.81, 1.53 ]
Total events: 77 (Antioxidant(s)), 69 (Control)
Heterogeneity: Chi2 = 2.46, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 4.1. Comparison 4 Any antioxidants versus control or placebo (subgroups by gestation at entry),
Outcome 1 Pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 4 Any antioxidants versus control or placebo (subgroups by gestation at entry)
Outcome: 1 Pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 12 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 12 - 20 weeks
Beazley 2002 9/52 9/48 11.5 % 0.92 [ 0.40, 2.13 ]
Sharma 2003 10/116 24/135 14.1 % 0.48 [ 0.24, 0.97 ]
Subtotal (95% CI) 168 183 25.7 % 0.64 [ 0.34, 1.20 ]
Total events: 19 (Antioxidant(s)), 33 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.35, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 1.39 (P = 0.16)
3 14 - 21+6 weeks
Poston 2006 181/1196 187/1199 26.5 % 0.97 [ 0.80, 1.17 ]
Rumbold 2006 56/935 47/942 21.9 % 1.20 [ 0.82, 1.75 ]
Subtotal (95% CI) 2131 2141 48.4 % 1.01 [ 0.86, 1.20 ]
Total events: 237 (Antioxidant(s)), 234 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
4 < 16 weeks
Mahdy 2004 1/46 2/67 2.2 % 0.73 [ 0.07, 7.80 ]
Subtotal (95% CI) 46 67 2.2 % 0.73 [ 0.07, 7.80 ]
Total events: 1 (Antioxidant(s)), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
5 16 - 22 weeks
Chappell 1999 11/141 24/142 14.6 % 0.46 [ 0.24, 0.91 ]
Subtotal (95% CI) 141 142 14.6 % 0.46 [ 0.24, 0.91 ]
Total events: 11 (Antioxidant(s)), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
6 < 26 weeks
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(. . . Continued)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Steyn 2002 3/100 3/100 4.6 % 1.00 [ 0.21, 4.84 ]
Subtotal (95% CI) 100 100 4.6 % 1.00 [ 0.21, 4.84 ]
Total events: 3 (Antioxidant(s)), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 < 29 weeks
Rivas 2000 1/63 14/64 3.0 % 0.07 [ 0.01, 0.54 ]
Subtotal (95% CI) 63 64 3.0 % 0.07 [ 0.01, 0.54 ]
Total events: 1 (Antioxidant(s)), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
8 21 - 28 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 > 28 weeks
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Unclear - ”during late pregnancy”
Han 1994 0/52 4/48 1.5 % 0.10 [ 0.01, 1.86 ]
Subtotal (95% CI) 52 48 1.5 % 0.10 [ 0.01, 1.86 ]
Total events: 0 (Antioxidant(s)), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 2701 2745 100.0 % 0.73 [ 0.51, 1.06 ]
Total events: 272 (Antioxidant(s)), 314 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 18.20, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 1.67 (P = 0.095)
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Analysis 4.2. Comparison 4 Any antioxidants versus control or placebo (subgroups by gestation at entry),
Outcome 2 Severe pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 4 Any antioxidants versus control or placebo (subgroups by gestation at entry)
Outcome: 2 Severe pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 - 20 weeks
Beazley 2002 3/48 3/52 5.1 % 1.08 [ 0.23, 5.11 ]
Subtotal (95% CI) 48 52 5.1 % 1.08 [ 0.23, 5.11 ]
Total events: 3 (Antioxidant(s)), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 14 - 21+6 weeks
Poston 2006 68/1196 54/1199 94.9 % 1.26 [ 0.89, 1.79 ]
Subtotal (95% CI) 1196 1199 94.9 % 1.26 [ 0.89, 1.79 ]
Total events: 68 (Antioxidant(s)), 54 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 1244 1251 100.0 % 1.25 [ 0.89, 1.76 ]
Total events: 71 (Antioxidant(s)), 57 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
0.1 0.2 0.5 1 2 5 10
Favours antioxidants Favours control
74Antioxidants for preventing pre-eclampsia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Any antioxidants versus control or placebo (subgroups by gestation at entry),
Outcome 3 Preterm birth.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 4 Any antioxidants versus control or placebo (subgroups by gestation at entry)
Outcome: 3 Preterm birth
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 - 20 weeks
Beazley 2002 20/52 14/48 3.0 % 1.32 [ 0.75, 2.31 ]
Subtotal (95% CI) 52 48 3.0 % 1.32 [ 0.75, 2.31 ]
Total events: 20 (Antioxidant(s)), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
2 14 - 21+6
Poston 2006 400/1372 373/1376 76.0 % 1.08 [ 0.95, 1.21 ]
Rumbold 2006 64/932 63/935 12.8 % 1.02 [ 0.73, 1.43 ]
Subtotal (95% CI) 2304 2311 88.9 % 1.07 [ 0.95, 1.20 ]
Total events: 464 (Antioxidant(s)), 436 (Control)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 16 - 22 weeks
Chappell 1999 6/141 5/142 1.0 % 1.21 [ 0.38, 3.87 ]
Subtotal (95% CI) 141 142 1.0 % 1.21 [ 0.38, 3.87 ]
Total events: 6 (Antioxidant(s)), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 < 26 weeks
Steyn 2002 50/100 35/100 7.1 % 1.43 [ 1.03, 1.99 ]
Subtotal (95% CI) 100 100 7.1 % 1.43 [ 1.03, 1.99 ]
Total events: 50 (Antioxidant(s)), 35 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 2597 2601 100.0 % 1.10 [ 0.99, 1.22 ]
Total events: 540 (Antioxidant(s)), 490 (Control)
Heterogeneity: Chi2 = 3.14, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
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Analysis 4.4. Comparison 4 Any antioxidants versus control or placebo (subgroups by gestation at entry),
Outcome 4 Small-for-gestational age.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 4 Any antioxidants versus control or placebo (subgroups by gestation at entry)
Outcome: 4 Small-for-gestational age
Study or subgroup Antioxidant Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 - 20 weeks
Beazley 2002 2/52 4/48 2.8 % 0.46 [ 0.09, 2.41 ]
Sharma 2003 14/116 32/135 14.7 % 0.51 [ 0.29, 0.91 ]
Subtotal (95% CI) 168 183 17.6 % 0.50 [ 0.29, 0.87 ]
Total events: 16 (Antioxidant), 36 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
2 14 - 21+6
Poston 2006 403/1393 360/1391 33.9 % 1.12 [ 0.99, 1.26 ]
Rumbold 2006 80/924 92/929 26.6 % 0.87 [ 0.66, 1.16 ]
Subtotal (95% CI) 2317 2320 60.5 % 1.02 [ 0.81, 1.29 ]
Total events: 483 (Antioxidant), 452 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.20 (P = 0.84)
3 16 - 22 weeks
Chappell 1999 33/141 45/142 22.0 % 0.74 [ 0.50, 1.08 ]
Subtotal (95% CI) 141 142 22.0 % 0.74 [ 0.50, 1.08 ]
Total events: 33 (Antioxidant), 45 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 2626 2645 100.0 % 0.83 [ 0.62, 1.11 ]
Total events: 532 (Antioxidant), 533 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 12.54, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.26 (P = 0.21)
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Analysis 4.5. Comparison 4 Any antioxidants versus control or placebo (subgroups by gestation at entry),
Outcome 5 Any baby death.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 4 Any antioxidants versus control or placebo (subgroups by gestation at entry)
Outcome: 5 Any baby death
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 14 - 21+6
Poston 2006 51/1393 39/1391 56.6 % 1.31 [ 0.87, 1.97 ]
Rumbold 2006 12/935 17/942 24.6 % 0.71 [ 0.34, 1.48 ]
Subtotal (95% CI) 2328 2333 81.2 % 1.13 [ 0.79, 1.61 ]
Total events: 63 (Antioxidant(s)), 56 (Control)
Heterogeneity: Chi2 = 2.01, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.65 (P = 0.51)
2 16 - 22 weeks
Chappell 1999 1/141 2/142 2.9 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 141 142 2.9 % 0.50 [ 0.05, 5.49 ]
Total events: 1 (Antioxidant(s)), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
3 < 26 weeks
Steyn 2002 13/100 11/100 16.0 % 1.18 [ 0.56, 2.51 ]
Subtotal (95% CI) 100 100 16.0 % 1.18 [ 0.56, 2.51 ]
Total events: 13 (Antioxidant(s)), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Total (95% CI) 2569 2575 100.0 % 1.12 [ 0.81, 1.53 ]
Total events: 77 (Antioxidant(s)), 69 (Control)
Heterogeneity: Chi2 = 2.46, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 5.1. Comparison 5 Any antioxidants versus control or placebo (subgroups by antioxidant type),
Outcome 1 Pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 5 Any antioxidants versus control or placebo (subgroups by antioxidant type)
Outcome: 1 Pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin C and E alone
Beazley 2002 9/52 9/48 11.5 % 0.92 [ 0.40, 2.13 ]
Chappell 1999 11/141 24/142 14.6 % 0.46 [ 0.24, 0.91 ]
Poston 2006 181/1196 187/1199 26.5 % 0.97 [ 0.80, 1.17 ]
Rumbold 2006 56/935 47/942 21.9 % 1.20 [ 0.82, 1.75 ]
Subtotal (95% CI) 2324 2331 74.5 % 0.92 [ 0.68, 1.25 ]
Total events: 257 (Antioxidant(s)), 267 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 5.89, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.53 (P = 0.60)
2 Vitamin C and E with other agents
Rivas 2000 1/63 14/64 3.0 % 0.07 [ 0.01, 0.54 ]
Subtotal (95% CI) 63 64 3.0 % 0.07 [ 0.01, 0.54 ]
Total events: 1 (Antioxidant(s)), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
3 Vitamin C alone
Steyn 2002 3/100 3/100 4.6 % 1.00 [ 0.21, 4.84 ]
Subtotal (95% CI) 100 100 4.6 % 1.00 [ 0.21, 4.84 ]
Total events: 3 (Antioxidant(s)), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Lycopene
Sharma 2003 10/116 24/135 14.1 % 0.48 [ 0.24, 0.97 ]
Subtotal (95% CI) 116 135 14.1 % 0.48 [ 0.24, 0.97 ]
Total events: 10 (Antioxidant(s)), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
5 Red palm oil
Mahdy 2004 1/46 2/67 2.2 % 0.73 [ 0.07, 7.80 ]
Subtotal (95% CI) 46 67 2.2 % 0.73 [ 0.07, 7.80 ]
Total events: 1 (Antioxidant(s)), 2 (Control)
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(. . . Continued)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
6 Selenium
Han 1994 0/52 4/48 1.5 % 0.10 [ 0.01, 1.86 ]
Subtotal (95% CI) 52 48 1.5 % 0.10 [ 0.01, 1.86 ]
Total events: 0 (Antioxidant(s)), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 2701 2745 100.0 % 0.73 [ 0.51, 1.06 ]
Total events: 272 (Antioxidant(s)), 314 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 18.20, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 1.67 (P = 0.095)
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Analysis 5.2. Comparison 5 Any antioxidants versus control or placebo (subgroups by antioxidant type),
Outcome 2 Severe pre-eclampsia.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 5 Any antioxidants versus control or placebo (subgroups by antioxidant type)
Outcome: 2 Severe pre-eclampsia
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and E alone
Beazley 2002 3/48 3/52 5.1 % 1.08 [ 0.23, 5.11 ]
Poston 2006 68/1196 54/1199 94.9 % 1.26 [ 0.89, 1.79 ]
Total (95% CI) 1244 1251 100.0 % 1.25 [ 0.89, 1.76 ]
Total events: 71 (Antioxidant(s)), 57 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 5.3. Comparison 5 Any antioxidants versus control or placebo (subgroups by antioxidant type),
Outcome 3 Preterm birth.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 5 Any antioxidants versus control or placebo (subgroups by antioxidant type)
Outcome: 3 Preterm birth
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and E alone
Beazley 2002 20/52 14/48 3.0 % 1.32 [ 0.75, 2.31 ]
Chappell 1999 6/141 5/142 1.0 % 1.21 [ 0.38, 3.87 ]
Poston 2006 400/1372 373/1376 76.0 % 1.08 [ 0.95, 1.21 ]
Rumbold 2006 64/932 63/935 12.8 % 1.02 [ 0.73, 1.43 ]
Subtotal (95% CI) 2497 2501 92.9 % 1.08 [ 0.96, 1.20 ]
Total events: 490 (Antioxidant(s)), 455 (Control)
Heterogeneity: Chi2 = 0.65, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Vitamin C and E with other agents
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vitamin C alone
Steyn 2002 50/100 35/100 7.1 % 1.43 [ 1.03, 1.99 ]
Subtotal (95% CI) 100 100 7.1 % 1.43 [ 1.03, 1.99 ]
Total events: 50 (Antioxidant(s)), 35 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
4 Lycopene
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Red palm oil
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
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(. . . Continued)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Selenium
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2597 2601 100.0 % 1.10 [ 0.99, 1.22 ]
Total events: 540 (Antioxidant(s)), 490 (Control)
Heterogeneity: Chi2 = 3.14, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
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Analysis 5.4. Comparison 5 Any antioxidants versus control or placebo (subgroups by antioxidant type),
Outcome 4 Small-for-gestational age.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 5 Any antioxidants versus control or placebo (subgroups by antioxidant type)
Outcome: 4 Small-for-gestational age
Study or subgroup Antioxidant Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin C and E alone
Beazley 2002 2/52 4/48 2.8 % 0.46 [ 0.09, 2.41 ]
Chappell 1999 33/141 45/142 22.0 % 0.74 [ 0.50, 1.08 ]
Poston 2006 403/1393 360/1391 33.9 % 1.12 [ 0.99, 1.26 ]
Rumbold 2006 80/924 92/929 26.6 % 0.87 [ 0.66, 1.16 ]
Subtotal (95% CI) 2510 2510 85.3 % 0.93 [ 0.73, 1.19 ]
Total events: 518 (Antioxidant), 501 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 6.78, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Vitamin C and E with other agents
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vitamin C alone
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Lycopene
Sharma 2003 14/116 32/135 14.7 % 0.51 [ 0.29, 0.91 ]
Subtotal (95% CI) 116 135 14.7 % 0.51 [ 0.29, 0.91 ]
Total events: 14 (Antioxidant), 32 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
5 Red palm oil
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Selenium
Subtotal (95% CI) 0 0 Not estimable
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(. . . Continued)
Study or subgroup Antioxidant Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Antioxidant), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2626 2645 100.0 % 0.83 [ 0.62, 1.11 ]
Total events: 532 (Antioxidant), 533 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 12.54, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.26 (P = 0.21)
0.01 0.1 1 10 100
Favours antioxidants Favours control
Analysis 5.5. Comparison 5 Any antioxidants versus control or placebo (subgroups by antioxidant type),
Outcome 5 Any baby death.
Review: Antioxidants for preventing pre-eclampsia
Comparison: 5 Any antioxidants versus control or placebo (subgroups by antioxidant type)
Outcome: 5 Any baby death
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and E alone
Chappell 1999 1/141 2/142 2.9 % 0.50 [ 0.05, 5.49 ]
Poston 2006 51/1393 39/1391 56.6 % 1.31 [ 0.87, 1.97 ]
Rumbold 2006 12/935 17/942 24.6 % 0.71 [ 0.34, 1.48 ]
Subtotal (95% CI) 2469 2475 84.0 % 1.10 [ 0.78, 1.57 ]
Total events: 64 (Antioxidant(s)), 58 (Control)
Heterogeneity: Chi2 = 2.44, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.56 (P = 0.58)
2 Vitamin C and E with other agents
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours antioxidants Favours control
(Continued . . . )
83Antioxidants for preventing pre-eclampsia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Antioxidant(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Vitamin C alone
Steyn 2002 13/100 11/100 16.0 % 1.18 [ 0.56, 2.51 ]
Subtotal (95% CI) 100 100 16.0 % 1.18 [ 0.56, 2.51 ]
Total events: 13 (Antioxidant(s)), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
4 Lycopene
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Red palm oil
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Selenium
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antioxidant(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2569 2575 100.0 % 1.12 [ 0.81, 1.53 ]
Total events: 77 (Antioxidant(s)), 69 (Control)
Heterogeneity: Chi2 = 2.46, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
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Last assessed as up-to-date: 26 October 2007.
Date Event Description
16 May 2012 Amended Contact details updated.
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H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 4, 2005
Date Event Description
4 February 2008 Amended Converted to new review format.
26 October 2007 New citation required and conclusions have changed The conclusions have changed: the evidence from this
review does not support routine antioxidant supplemen-
tationduringpregnancy to reduce the risk of pre-eclamp-
sia and other serious complications in pregnancy
26 October 2007 New search has been performed Search updated inMay 2007.We identified 15new trials.
Four have been included (Mahdy 2004;Merchant 2005;
Poston 2006; Rumbold 2006); three are awaiting assess-
ment (Kubik 2004; Negro 2007; Rumiris 2006) and
eight have been excluded (Borna 2005; Casanueva 2005;
Dijkhuizen 2004; Radhika 2003; Roes 2006; Theobald
1937; Thomson 2001; West 1999). We moved one
study from the included to the excluded studies (People’s
League 1942) because we now exclude quasi-random
studies - see differences between protocol and review
C O N T R I B U T I O N S O F A U T H O R S
Alice Rumbold and Lelia Duley developed and wrote the protocol. Caroline Crowther and Ross Haslam commented on and revised
the various drafts of the protocol during its development. Alice Rumbold and Caroline Crowther extracted the data. Alice Rumbold
wrote the first draft of the review. Lelia Duley, Caroline Crowther and Ross Haslam commented on various versions of the review.
For the 2007 update, Alice Rumbold, Caroline Crowther and Lelia Duley extracted the data. Alice Rumbold wrote the first draft of
the updated review. Lelia Duley, Caroline Crowther and Ross Haslam commented on various versions of the review.
D E C L A R A T I O N S O F I N T E R E S T
Caroline Crowther and Ross Haslam were chief investigators for the Australian Collaborative Trial of Supplements with vitamin C
and vitamin E for the prevention of pre-eclampsia (ACTS). Alice Rumbold was the PhD student involved with this trial (ACTS).
Lelia Duley was a member of the steering committee for the Vitamins in Pregnancy (VIP) trial, which assessed vitamins C and E for
prevention of pre-eclampsia.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Discipline of Obstetrics and Gynaecology, The University of Adelaide, Australia.
• Medical Research Council, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We excluded quasi-random studies. The previous version of this review included quasi-random studies; we planned to exclude quasi-
random studies from future updates of the review, when sufficient data became available from large randomised controlled trials.
We added the following new outcomes: gestational hypertension, use of antihypertensives, miscarriage, extremely preterm birth (less
than 27 completed weeks’ gestation), Apgar score less than seven at five minutes and economic outcomes. These outcomes were added
to ensure all outcomes specified in the pre-eclampsia generic protocol are reported in this review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antioxidants [∗therapeutic use]; Infant, Newborn; Infant, Small for Gestational Age; Oxidative Stress; Pre-Eclampsia [∗prevention &
control]; Pregnancy Outcome; Premature Birth [etiology]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
86Antioxidants for preventing pre-eclampsia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
